SCIENTIFIC DISCUSSION

This module reflects the initial scientific discussion for the approval of Ariclaim. For information on changes after approval please refer to module 8.

1. Introduction

Boehringer Ingelheim International GmbH has submitted a Marketing Authorisation Application through the Centralised Procedure, for the medicinal product Ariclaim, containing duloxetine hydrochloride, for the treatment of stress urinary incontinence (SUI).

This is a complete and independent marketing authorisation application, as stated in Art. 8 (3) of Directive 2001/83/EC, as amended. The provided data cover all aspects of the clinical characterization of safety and efficacy of duloxetine. The applicant has submitted the results of non-clinical and clinical studies carried out for the application.

Urinary incontinence is defined by the International Continence Society as the complaint of any involuntary leakage of urine. It is a common and chronic condition in women. While not life-threatening, it can have a significant negative impact on the psychological well-being, social functioning and overall quality of life of those affected.

Urinary incontinence not only causes considerable personal discomfort but also has a relevant health economic impact. It has been reported a median prevalence in adults (of any type or amount of incontinence) of 28% (range, 12% to 42%) in women younger than 60 years, and 35% (range, 17% to 55%) in women 60 years and older. The prevalence of daily incontinence is 4% (range, 2% to 11%) in women younger than 60 years, and 14% (range, 3% to 17%) in women 60 years and older.

Among women younger than 60 years who reported incontinence, about half had stress incontinence. For women 60 years and older, the rate of stress incontinence was lower, with only approximately 25% of incontinence due to stress; the remainder was caused by either urge or mixed urge-stress incontinence.

Urinary incontinence in women can be broadly divided into two main types: stress (effort) urinary incontinence and urge incontinence. The term mixed incontinence denotes the concomitant appearance of stress and urge incontinence.

Stress urinary incontinence is defined by the International Continence Society as the complaint of involuntary leakage of urine on effort or exertion, or on sneezing or coughing (Abrams et al. 2000). Anatomically, most SUI results from diminished function of the pelvic floor structures that provide support for the pelvic organs, leading to hypermobility and descent of the bladder and urethra. SUI is the most common type of urinary incontinence in women, with 78% of incontinent women presenting with the symptom of SUI in either pure (43%) or mixed (29%) forms.

In SUI leakage appears when the intra-abdominal pressure increases above the forces contributing to the urethral closure pressure. Under resting condition paraurethral muscles usually maintain a pressure (resting urethral closure pressure-RUCP) that prevents leakage of urine. When intra-abdominal pressure is increased above the RUCP, in continent women the abdominal pressure is transmitted to the urethra via surrounding tissues to maintain a positive UCP. A woman will leak urine on exertion if pressure transmission is insufficient and the force (pressure generation) of the exertion is above the UCP. Thus, there are two factors that contribute to continence: the resting urethral pressure and the transmission of pressure from outside to the urethra on exertion.

Treatment of SUI

In SUI surgery is generally regarded as the method with best chances of cure or significant improvement.

Conservative and surgical treatments will depend on the patient’s preference, condition, and urodynamic diagnosis.

Conservative treatment is indicated when patients refuse or are undecided about surgery, they are physically or mentally unfit for surgery, or childbearing is incomplete:

a) Pelvic floor muscle training (PFMT) is a non-invasive method and should be considered as the first option for all patients with stress incontinence. It concerns re-education of the pelvic floor muscles by encouraging women to voluntarily contract their pelvic floor muscles. The overall rate for cure or
much improvement at five years is high. However, its success is reliant upon the patient’s motivation and commitment.

PFMT has been the subject of a recent Cochrane review 1. The reviewers conclude "pelvic floor muscle training appeared to be an effective treatment for adult women with stress or mixed incontinence. Pelvic floor muscle training was better than no treatment or placebo treatment. The limitations of the evidence available mean that it is difficult to judge if pelvic floor muscle training was better or worse than other treatments. Most trials to date have studied the effect of treatment in younger, premenopausal women." The reviewers also state "Long term results of pelvic floor muscle training are unclear. Side effects of pelvic floor muscle training were uncommon and reversible."

In the Cochrane review, studies that compared PFMT with no treatment in SUI have been pooled. Self reported cure appeared in 17% of treated women and in 2% of untreated women. Self reported cure or improvement was reported in 79% of treated versus 3.5% of untreated women. Both differences were highly statistically significant, as was the reduction in the number of incontinence episodes. The review also concluded, based on three trials, that PFMT is better than placebo treatment. However, only one of the three placebo-controlled trials was a blinded trial using an imitation PFMT regimen. It showed identical responses for the real and placebo PFMT regimens. The results of this study are supported by the results of the Applicant’s study SBAF, considered later in this summary. The other two placebo-controlled trials cited in the Cochrane report did not use a control for PFMT. One used a placebo pill in an urge incontinent population and the second used an inactive electrical stimulation device in a stress incontinent population.

b) Devices such as electrical stimulation (stimulation of the pudendal nerve with electrodes placed in the vagina or anus), elevating devices (that support the bladder neck) or occlusive devices (for occluding the urethra) are also been employed. Compliance seems to be a major problem, and patient also needs sufficient manual dexterity. Side effects include urinary tract infections, and soreness of the vaginal mucosa.

c) Surgery is indicated when conservative treatment fails or the patient wants definitive treatment. The different techniques of continence surgery aim to elevate and stabilise the bladder neck and urethra via either the vaginal or abdominal route; sling techniques that provide midurethral support, and techniques that provide urethral compression increasing its resistance. In general, the first attempt at continence surgery produces better results than repeat procedures. Clinical features, urodynamic data, and operation characteristics influence the choice of surgery, and the success rates vary. Meta-analyses of published studies indicate that anterior repair procedures provide similar short-term results to colposuspension; however, long-term efficacy is of the order of 40%. The immediate and long-term results of colposuspension and various sling procedures appear similar with efficacy in the 70 to 90% range. Side effects include prolapse, suture pain or infection, new detrusor instability or lower tract damage.

No pharmacological treatment has been widely approved for the treatment of women with SUI. Duloxetine is a combined serotonin (5-HT, 5-hydroxytryptamine) and norepinephrine (NE) reuptake inhibitor (SNRI). It weakly inhibits dopamine reuptake and has no significant affinity for histaminergic, dopaminergic, and cholinergic or adrenergic receptors. Due to its neuromodulatory action, duloxetine is believed to increase urethral tone and probably bladder capacity and thereby reduces stress urinary incontinence (SUI).

Ariclaim 40 and 20 mg capsules contain enteric-coated pellets of the active substance duloxetine hydrochloride ((+)-(S)-N-methyl-γ-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride) equivalent to 40 and 20 mg of duloxetine. Duloxetine is intended for women with Stress Urinary Incontinence (SUI).

The effectiveness of duloxetine in the treatment of SUI is believed to be linked to its inhibition of presynaptic neuron reuptake of serotonin and norepinephrine in the central nervous system (sacral spinal cord) resulting in elevated levels of serotonin and norepinephrine in the synaptic cleft. The recommended posology is a dose of 40 mg twice daily without regard to meals. After 2-4 weeks of treatment, patients should be re-assessed in order to evaluate the benefit and tolerability of the

---

If a woman experiences troublesome adverse events beyond 4 weeks, the dose can be reduced to 20 mg twice daily. Based on this posology, a combined package leaflet including both strengths has been adopted. Scientific Advice on the clinical development of Ariclaim was given by the CHMP on November 19th, 1998.

2. Chemical, pharmaceutical and biological aspects

Introduction

The product is presented in the form of hard gastro-resistant capsules containing enteric-coated pellets and it contains duloxetine hydrochloride equivalent to 20 mg and 40 mg of duloxetine base as active substance. Other ingredients are sucrose, hydroxypropyl methylcellulose, sugar, talc, gelatine, colorants, etc. The capsules are packaged in Polyvinylchloride (PVC), Polyethylene (PE), and Polychlorotrifluoroethylene (PCTFE) blisters sealed with an aluminium foil.

Active substance

Duloxetine hydrochloride is an active substance not described in any Pharmacopoeia. Duloxetine hydrochloride has the chemical name (+)-(S)-N-methyl-γ-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride is a white to practically white solid, and is slightly soluble in water; its solubility is not pH dependent. The chemical structure of duloxetine hydrochloride is well characterised. It is an optically active molecule, which presents 1 asymmetric carbon, therefore two enantiomers are possible. The S enantiomer has been selected based on both in vitro and in vivo studies. Selecting the correct chiral starting materials controls the optical purity of the drug substance. According to the manufacturing process described, the S-enantiomer is routinely obtained and the R-enantiomer is considered as a specified impurity.

Two manufacturing processes synthesize Duloxetine hydrochloride. Both processes are equivalent. Batch analysis data allow for the conclusion that the analytical profiles are similar between batches. Adequate In-Process Controls are applied during the manufacture of duloxetine active substance. The specifications and control methods for intermediate products, starting materials and reagents, have been presented and are satisfactory.

Active substance specifications

The active substance specification includes tests for physical characteristics of the active substance, identity, assay, process and product related impurities, as well as additional pharmacopoeia testing requirements consistent with this dosage form.

The specifications reflect all relevant quality attributes of the active substance and were found to be adequate to control the quality of the drug substance. Batch analysis data of a number of batches of active substance are provided. The results are within the specifications and consistent from batch to batch.

Stability

Stability studies for primary batches (manufactured by one of two alternative processes) from storage under long term ICH conditions (30°C/60%RH) up to 24 months and under stress conditions (40°C / 75% RH) up to 6 months were provided. Supportive data was provided in terms of data from six batches manufactured by the same process as for the primary batches and for six batches manufactured by the second process. The batches were packed in a linear low-density polyethylene liner (LLDPE) placed inside a laminated foil liner. The parameters evaluated were stability indicating. Methods are validated and stability indicating.

The re-test period proposed is acceptable taking into account the results obtained in formal stability studies and the supportive stability data.
Other ingredients

The excipients in the capsule content are: hypromellose, hydroxypropyl methylcellulose acetate succinate sugar spheres, sucrose, talc, ammonium hydroxide, triethyl citrate, and titanium dioxide (E 170) and in the capsule shell are: gelatin, sodium lauryl sulfate, colorants and ink. All of them are included in compendial monographs.

Analytical certificates of excipients are included. Specifications and analytical certificates for the capsules and the printing ink are presented.

Animal-derived products utilised in the manufacturing process met compliance standards for the control of transmissible spongiform encephalopathies (TSE). The Gelatin used in the capsules shell is complies with EMEA/CHMP/4306/00 and CHMP/BWP/1230/98 for sourcing and processing of gelatin for the control of TSE in products for human use. TSE certificates of suitability are presented.

Duloxetine capsules are packaged in Polyvinylchloride (PVC), Polyethylene (PE), and Polychlorotrifluoroethylene (PCTFE) blisters sealed with an aluminium foil. The choice of materials for the container is adequate for the type of product and moreover supported by the stability studies performed.

Product development and finished product

Duloxetine hydrochloride is acid-labile substance; therefore, the product development has been focus to develop an enteric-coated dosage form in order to prevent degradation of the active substance in the acidic environment of the stomach. Hard gastro-resistant capsules with enteric-coated pellets were selected after development of some formulations to be the optimal market formulation.

The product is manufactured in accordance to conventional processes for this pharmaceutical form. The manufacturing process has been adequately validated by a number of studies for the major steps of the manufacturing process in three batches produced for stability studies and clinical trials.

The validation show that the hard capsules can be manufactured reproducibly according to the agreed finished product specification, which is suitable for control of this oral preparation

Product Specification

The specification includes tests by validated methods for physical appearance, identity assay product and process related impurities, as well as additional pharmacopeia testing requirements consistent with this dosage form.

The test and limits of the release and shelf life specification for the finished product are appropriate to control the quality of this medicinal product for its intended purpose.

Batch data are provided for pilot and production batches and indicate satisfactory uniformity as well as compliance with the specification.

Stability of the Finished Product

36 months data generated under ICH conditions are presented in the primary stability study. The parameters evaluated were stability indicating. A supplementary stability study was also conducted to address the effect of the capsule shell colours in stability.

Photostability testing was conducted according to the ICH guideline for photostability testing of new active substances and medicinal products. The results indicate that the drug substance in the capsule formulation is chemically stable with respect to light.

Based on available stability data, the proposed shelf life and storage conditions as stated in the SPC are acceptable.

Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the drug substance and drug product have been presented in a satisfactory manner. The results of tests carried out indicate satisfactory consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in the clinic.
3. **Toxico-pharmacological aspects**

**Introduction**

Duloxetine is a combined serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor (SNRI) that weakly inhibits dopamine reuptake and has no significant affinity for histaminergic, dopaminergic, and cholinergic or adrenergic receptors. Due to its neuromodulatory action, duloxetine is believed to increase urethral tone and probably bladder capacity and thereby reduces SUI. However, the Applicant has not been able to properly describe the mechanism of action of duloxetine in patients with SUI, and additional studies are considered necessary in order to further elucidate it.

The excipients used in the formulation of the product are generally recognised as safe (GRAS) compounds, with the exception of hydroxypropyl methylcellulose acetate succinate, and are widely used in oral pharmaceutical preparations.

Studies carried out to assess general pharmacodynamics and toxicology of hydroxypropyl methylcellulose acetate succinate indicate that it is poorly absorbed and is excreted predominantly in the faeces, with no significant toxic effects and therefore, does not appear to pose a toxicological liability as an enteric coating for duloxetine capsule.

The Applicant has submitted extensive documentation concerning nonclinical pharmacology and toxicology of duloxetine, as well as for related substances and impurities, and excipients included in the formulation.

The development programme of duloxetine was long, with initial toxicology studies being conducted in the mid-1980s. The first directive concerning the application of the Good Laboratory Practices (GLPs) in non-clinical studies carried out with chemical and pharmaceutical products dates 1987 (87/18/EEC) and therefore, several non-clinical studies were not carried out specifically under GLP standards. Studies previously conducted included in this dossier were carried out following previously established analytic procedures, with an extensively description of the material and methods used, and reviewed by the scientific committee where these studies were published, that guarantee their quality. The rest of the studies were performed in accordance with Good Laboratory Practise standards.

**Pharmacology**

- **Primary pharmacodynamics (in vitro/in vivo)**

  Reuptake by nerve endings is thought to be a primary mechanism for removing monoamines from the synapse and terminating their effects at pre- and post-synaptic receptors. Therefore, blockade of reuptake may increase synaptic levels of monoamines and enhance monoaminergic neurotransmission. The effectiveness of duloxetine in the treatment of SUI is linked to its inhibition of presynaptic neuron reuptake of serotonin and norepinephrine in the central nervous system, resulting in elevated levels of serotonin and norepinephrine in the synaptic cleft.

- **In vitro studies**

  *In vitro*, duloxetine inhibits the uptake of 5-HT and NE. It weakly inhibits dopamine reuptake and has no significant affinity for histaminergic, dopaminergic, cholinergic or adrenergic receptors. Furthermore, duloxetine has relatively weak affinity in vitro for other neuronal receptors and binding sites. None of the various hydroxy-substituted compounds had appreciable affinity for the 5-HT, NE and dopamine transporters. The R (-) enantiomer of duloxetine, was also a potent inhibitor of 5-HT and NE reuptake.

  Studies evaluating the pharmacodynamic potential of metabolites and/or degradation products of duloxetine were performed. Although several potential metabolites, in addition to the 1-naphthol acid degradation product, bound to neurotransmitter receptors, none of the circulating metabolites have demonstrable pharmacological activity.

- **In vivo studies**

  Pharmacodynamics directly related to the molecule must be inferred for claims toward the intended clinical utility of duloxetine, as specific animal models for stress urinary incontinence are not
available. The models described provide indirect pharmacological evidence for the potential clinical efficacy of the molecule.

The effects of duloxetine on lower urinary tract function were evaluated in the cat animal model. Duloxetine produced dose-dependent increases in bladder capacity in all 9 cats tested, to about five times the capacity seen under control conditions.

Peri-urethral muscle EMG activity increased dose-dependently, following administration of duloxetine. During the filling phase of the cystomyogram (CMG) profile, activity increased up to 8 times control levels at a dose of 0.3 mg/kg with larger doses producing no greater effect on average. This increase in EMG activity was seen in all 9 cats. The effects on urinary bladder activity were centrally mediated, since bladder contractions evoked by electrical stimulation of efferent fibers in the pelvic nerve were not affected by duloxetine. The increases in urinary bladder capacity and sphincter EMG activity produced by duloxetine are effects that would promote normalisation of urinary bladder function, thereby preventing the accidental loss of urine as seen in SUI.

- Secondary pharmacodynamics

Since 5-HT and NE are implicated in enhancing/mediating endogenous analgesic mechanisms, effects of duloxetine in chronic and acute pain were evaluated in several animal models. Results of these studies indicated that duloxetine was effective in models of persistent inflammatory or neuropathic pain, but not in models of acute pain. Duloxetine’s activity in the behavioural assays and in antidepressant models indicates enhancement of 5-HT and NE neurotransmission, in agreement with its mechanism of action. Moreover, duloxetine was found to decrease food consumption in a variety of rodent models.

- Safety pharmacology

The potential of duloxetine to alter cardiovascular, central nervous system (CNS), smooth muscle, renal, immune, and gastrointestinal motility functions, as well as its potential for substance abuse was examined as part of the safety pharmacology dossier provided by the Applicant.

Cardiovascular effects: *in vitro*, duloxetine maleate had no effect on the function of the smooth and cardiac muscles at concentrations of $10^{-6}$ M and lower, while antagonistic effects were observed at concentrations of $10^{-5}$ and above. Duloxetine did not affect smooth or cardiac muscle function of rat and guinea pig at concentrations of 1 nM to 1 µM.

Cardiac ion channel results, together with QT measurements from dogs and humans would not pose an arrhythmogenic risk with the use of duloxetine.

Central nervous system effects: Duloxetine would not be predicted to substantively affect CNS. It did not adversely affect CNS function of mice after single oral doses 3 mg/kg. At higher doses (10 and 30 mg/kg) an increase in hexobarbital-induced time sleep was observed, indicating that duloxetine may produce CNS depression or interfere with hexobarbital metabolism. Moreover, an increase in seizure threshold in electroshock-induced convulsions was observed at the highest dose. Comparable changes have been obtained following multiple dosing (5 days). Mydriasis has been reported in association with duloxetine treatment.

Gastrointestinal, renal and immunological effects: there were no important effects on gastrointestinal motility or immune functions in mice. Regarding renal function, no effects on urine volume were observed in rats based on the studies provided by the Applicant. However, a slight elevation of serum potassium levels and an increase in sodium excretion were observed with 10 and 20 mg/kg doses.

Potential for abuse: the abuse potential of duloxetine was evaluated in monkeys and rats; duloxetine demonstrated the above mentioned CNS effects in rats, but not in rhesus monkeys up to 64 mg/kg doses. Duloxetine also did not demonstrate cross physical dependence potential with barbital or physical dependence-producing potential. As such, duloxetine would not be expected to pose a risk for substance abuse.

Based upon the results of these studies, therapeutically relevant doses of duloxetine would not be predicted to substantively affect CNS, smooth muscle, renal, immune, or gastrointestinal functions, neither would be expected to pose a risk for substance abuse. Potential secondary pharmacologic
reactions at clinical doses would be limited to potential increases in pulmonary pressure, pulmonary vascular resistance, and respiratory rate. However, these effects are attributable to the known actions of norepinephrine and serotonin (Brunner and Gross 1979; Garattini and Valzelli 1965; Weiner 1985), and were only observed in anaesthetised animals.

- **Pharmacodynamic drug interactions**

Conventional drug-drug interaction studies showed no evidence of clinically important increases in adverse effects in patients when duloxetine was coadministered with lorazepam, ethanol, famotidine, aminophylline, desipramine, or paroxetine. Duloxetine does not exacerbate the adverse cognitive and psychomotor effects of ethanol but it appears to exacerbate the sedative effects of lorazepam. Caution is advised when duloxetine is taken in combination with other centrally acting drugs or substances, especially those with a similar mechanism of action, and including alcohol. Duloxetine should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/or seizures, when taken in combination with lorazepam or other centrally acting drugs with a similar mechanism of action as that of duloxetine.

- **Summary of salient findings**

The rationale for the development and application for marketing approval of the duloxetine formulation is well established. In vitro, duloxetine was an inhibitor of both serotonin and norepinephrine reuptake and a relatively weak inhibitor of dopamine reuptake. The molecule was active in urinary models indicative of enhancement of serotonin and norepinephrine neurotransmission, with improvement of capacity of the urinary bladder and increased urinary sphincter activity. These results from in vivo studies indicate that duloxetine-induced inhibition of 5-HT and NE reuptake suppresses urinary bladder muscular activity in a dose-dependent manner, and enhances external urethral sphincter activity through centrally mediated (CNS) mechanism. At therapeutic range, duloxetine is not expected to pose a risk on CNS, smooth muscle, renal, immune, or gastrointestinal functions. Substance abuse is unlikely. The extent and scope of the documentation provided in this application are appropriate to support the non-clinical-pharmacology profile of duloxetine. All the non-clinical-pharmacology information provided is supported by relevant bibliographical references.

**Pharmacokinetics**

The Applicant has conducted a number of studies concerning the absorption, distribution, metabolism, and excretion of duloxetine in mice, rats, and dogs. Only limited metabolism and excretion were evaluated in the monkey, since the dog had been chosen as the nonrodent species for use in the toxicology programme. Radiolabeled drug was administered in the pharmacokinetic, metabolism, excretion, and tissue distribution studies. The plasma protein binding of 14C-duloxetine has been determined in mouse, rat, dog, and human plasma. Additional studies have investigated the placental transfer of 14C-duloxetine in rats and the excretion of 14C-duloxetine into milk of lactating rats.

- **Absorption- Bioavailability**

  The Applicant has conducted a number of studies concerning absorption of duloxetine in several animal species. Duloxetine was well absorbed in these species after gavage or dietary administration. After oral administration, duloxetine is well absorbed but extensively metabolised, $t_{\text{max}}$ being approx. 1.5 hours in mice and rats. Absorption was found to be greatest from the duodenum and least from the stomach. Additionally, pharmacokinetics of duloxetine were similar in fed and fasted male rats. Bioavailability was determined to be 21% in rats and 5% in dogs, probably due to extensive metabolism in the latter. No consistent gender differences in exposure occurred in dogs, although female rats tended to have higher exposure than male rats and male mice had greater values than female mice, but only at the highest doses tested. Even though the AUC values increased with increasing doses in mice, rats and
dogs, these increases were not always proportional at the higher doses. Additionally, there was no evidence of accumulation with increasing duration of exposure.

- Distribution

With respect to the distribution of duloxetine, several studies using quantitative whole-body autoradiography (QWBA) and tissue dissection studies techniques were performed. Duloxetine was highly bound to proteins in plasma, the mean percent bound to human plasma proteins at a duloxetine concentration of 150.2 ng/mL being 95.9%. Duloxetine was present in high concentrations in the stomach and intestinal contents at 3 to 12 hours postdose. Kidney, liver, and lung contained the highest tissue concentrations. Duloxetine and/or its metabolites were distributed into breast milk of rats and does undergo placental transfer. Therefore, embryonic tissues were exposed to duloxetine and its metabolites during the period of organogenesis in the embryo-foetal toxicity studies. Although there was no embryo-foetotoxicity effect observed, delay in postnatal development was reported. In conclusion, duloxetine should not be administered during pregnancy as well as the breast-feeding period.

- Metabolism

The Applicant has performed a number of studies concerning metabolism of duloxetine in mice, rats, dogs, and monkeys. After oral administration, duloxetine was well absorbed, but extensively metabolised regardless of the salt form. Overall, the liver was determined to be the primary organ responsible for the metabolism of duloxetine. In all animal species, the major biotransformation pathways involve several oxidations, especially in the naphthyl ring followed by further oxidation and conjugation or formation of a dihydrodiol. Additional reactions involved cleavage at the ether linkage to form thienyl derivatives and naphthol. Some differences related to the metabolic profile and exposure exists between animal’s species and humans. Duloxetine was a mixed cytochrome P-450 inducer in all species tested, at higher doses CYP1A and CYP2B were induced), but there was no significant induction of CYP1A2 or CYP3A in cultured human hepatocytes. Both CYP2D6 and CYP1A2 participate in the biotransformation of 4-hydroxy and 5-hydroxy duloxetine, suggesting that the clearance of duloxetine would be related to the levels and activities of both of these enzymes.

- Excretion

The Applicant in mouse, rat, dog and human performed several excretion studies. The excretion profile was similar after either oral or intravenous administration to rats and dogs, which indicates that duloxetine was well absorbed and that elimination was not affected by the route of administration. Duloxetine was cleared rapidly primarily by metabolism in all species tested, and one or more of its metabolites has an extended elimination phase. Mice, rats, and dogs excreted the majority of a single oral dose of 14C-duloxetine in the faeces, whereas humans excreted a larger amount of the dose in urine. Further, approximately 66% of the radioactivity excreted in the bile is reabsorbed in rats, indicating that enterohepatic circulation of metabolite(s) likely contributes to the extended elimination phase of radioactivity in the animal species.

- Pharmacokinetic drug interactions

Duloxetine is a moderate inhibitor of CYP2D6, and therefore, caution is advisable if administering duloxetine together with other CYP2D6 inhibitors. Concomitant use of duloxetine with drugs undergoing CYP2D6 metabolism may result in higher concentrations of the latter. There was no significant induction of CYP1A2 or CYP3A in cultured human hepatocytes. Concomitant use of duloxetine with potent inhibitors of CYP1A2 will result in higher concentrations of duloxetine and therefore co-administration is not recommended.
Summary of pharmacokinetic parameters

The Applicant has appropriately described the non-clinical pharmacokinetics properties for duloxetine. A number of studies concerning the absorption, distribution, metabolism, and excretion of duloxetine in mice, rats, and dogs have been performed.

Rats might be suggested to be the most appropriate species for toxicology studies since major biotransformation pathways for duloxetine, in female rats as in man, were similar. However, mice and dogs are also valuable since exposure to specific human circulating metabolites could be seen in their plasma.

Duloxetine was well absorbed in the mentioned species, and absorption was maximum at the duodenum. It did not show evidence of accumulation when duration of exposure increased. Duloxetine presented high protein binding across all species. Although it is not widely distributed it crosses the blood-brain barrier, undergoes placental transfer and is excreted into milk. Duloxetine is extensively metabolised, primarily by the liver.

The main pharmacokinetics features are summarised in the following table:

Table 1. Summary of pharmacokinetics for duloxetine

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absorption</strong></td>
<td>Well absorbed. After oral administration: t&lt;sub&gt;max&lt;/sub&gt; = 1.5 hrs in mice, rats, dogs and monkeys; t&lt;sub&gt;max&lt;/sub&gt; = 6 hrs in humans; with food t&lt;sub&gt;max&lt;/sub&gt; delayed to 10 hrs (variable)</td>
</tr>
<tr>
<td><strong>Bioavailability</strong></td>
<td>Rat approximately 21%. Dog approximately 5%. Human approximately 50% (32%-80%)</td>
</tr>
<tr>
<td><strong>Dose proportionality</strong></td>
<td>Linear kinetics was seen in mice and rats. In dogs, linear kinetics was observed at low daily doses (&lt; 30 mg/kg). Non-linear at and above daily doses of 30 mg/kg in dog. Non-linear kinetics in humans</td>
</tr>
<tr>
<td><strong>Terminal plasma half-life</strong></td>
<td>Mouse: 2.1 hrs, radioactivity half life: 27 hrs Rat: 1.5 hrs, radioactivity half life: 122 hrs Dog: 4 hrs, radioactivity half life: 93 hrs Monkey: 3.5 hrs (2-12 hrs), radioactivity half life: 91 hrs Human: 12.1 hrs, radioactivity half life: 120 hrs</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>High protein binding (93.6%-97.3% in all species). Not widely distributed but crosses the blood-brain barrier. Distribution over placenta and excreted into milk.</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Rapid and extensive metabolism. Some differences related to the metabolic profile and exposure exists between animal’s species and humans.</td>
</tr>
<tr>
<td><strong>Excretion</strong></td>
<td>Mice, rats and dogs: main route via faeces (46%-77%). Monkey: main route via urine (58%) Human: main route via urine (72%) Biliary excretion in rats, dogs.</td>
</tr>
</tbody>
</table>
Toxicology

Duloxetine hydrochloride has been evaluated in a variety of toxicology studies in laboratory animals and in vitro test systems. Studies included single-dose toxicity in mice, rats, and dogs; repeated-dose toxicity in mice, rats, and dogs; in vitro and in vivo genotoxicity; carcinogenic potential in mice and rats; and reproductive and developmental toxicity in rats and rabbits. All toxicity studies were performed according to GLP.

• Single-dose toxicity

Single-dose toxicity studies were conducted with duloxetine hydrochloride and duloxetine maleate in mice, rats and dogs using oral administration, the intended clinical route. In general, the toxicologic effects seen in the three species were extensions of the pharmacology of duloxetine. The primary findings following oral administration were related to central nervous system (CNS) effects (i.e., tremors, convulsions, emesis, mydriasis, salivation, and hyper-responsiveness).

The median lethal doses in mice were approximately 300-400 mg/kg, and in rats 500-600 mg/kg (males) and 300-500 mg/kg (female). In dogs, no deaths occurred at the maximum tested dose of 100 mg/kg.

• Repeat-dose toxicity

Repeat-dose toxicity studies were conducted with duloxetine hydrochloride and duloxetine maleate in mice, rats and dogs using dietary (mice and rats) or gavage (dogs) administration. Altogether eight studies were performed.

Based on the results provided by the Applicant, the most relevant adverse events, target organ-related to duloxetine administration in all species tested was the liver, with signs occurring at or below the clinical exposure in all animal species investigated. The changes observed in this target organ did not appear to be indicative of toxicity, and they could have been a consequence of hepatic induction. Major findings were increased liver weights, moderate induction of hepatic enzymes (CYP1A1 and CYP2B) and slight to moderate centrilobular hypertrophy. Slight lipofuscin pigmentation was also noted in male mice.

• Genotoxicity in vitro and in vivo

Duloxetine maleate and duloxetine hydrochloride were not mutagenic when tested at appropriate doses in a battery of genotoxicity in vitro and in vivo studies that included all relevant positive controls. All studies were performed with duloxetine hydrochloride or maleate according to GLP. There was no evidence of induced mutation by treatment with duloxetine maleate and duloxetine hydrochloride when tested. Taking into account the results of these studies, duloxetine can be considered as a non-genotoxic substance.

• Carcinogenicity

The oncogenic/carcinogenic potential of duloxetine hydrochloride was evaluated in both mice and rats. The studies were performed according to GLP.

A dose-dependent increase in the percentage of cells with diplochromosomes was seen in the in vitro chromosomal aberration test in CHO cells. Hepatocytes with more than one nucleus are a common histological finding. However, hepatocytes with more than 2-3 nuclei are rare. Multinucleated cells were seen in the liver in the rat carcinogenicity study. The underlying mechanism is unknown. The multinucleated hepatocytes were observed as a dose-related effect in the rat carcinogenicity study without any sign of other pathological changes observed in the hepatocytes. No genotoxicity or hepatic tumourigenesis were observed. No multinucleated hepatocytes were seen in either the mouse or dog, which indicates a species-specific effect in the rat. However, the clinical relevance of this finding is unknown. To properly reflect this information, the following text is included in section 5.3 of the SPC: “Multinucleated cells were seen in the liver in the absence of other histopathological changes in the rat carcinogenicity study. The underlying mechanism and the clinical relevance are unknown.”
• Reproductive and developmental studies

Fertility studies were conducted by the Applicant to test reproductive performance in both male and female rats. Duloxetine had no effect on male fertility and effects in females were only evident at doses that caused maternal toxicity. Furthermore, foetal viability and morphology were not adversely affected by treatment. In a pre/postnatal toxicity study in rat, duloxetine induced adverse behavioural effects in the offspring at systemic exposures levels below maximum clinical exposure (AUC).

In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximum clinical exposure (AUC). No malformations were observed in another study testing a higher dose of a different salt of duloxetine. As a consequence of this, duloxetine is contraindicated during pregnancy.

• Local tolerance

Fischer 344 rats given daily 30-minute intravenous infusions at doses of 1, 5, or 10 mg/kg had findings of excessive irritation at the injection sites. Systemic toxicity was not observed in rats given 1 mg/kg/day for 15 days. Similarly, daily 30-minute intravenous infusions to beagle dogs at doses of 1, 2.5, or 5 mg/kg had no evidence of systemic toxicity. However, local irritation at the injection sites precluded dosing of the 5-mg/kg/day group for longer than 10 days.

• Other toxicity studies

The potential for immunogenicity and hypersensitivity-eliciting antigenicity of duloxetine was evaluated in a number of studies in guinea pigs and mice. Duloxetine was not immunogenic and does not possess hypersensitivity-eliciting antigenicity in any of the studies performed. These results indicate that the risk of duloxetine causing adverse allergic reactions is negligible.

The abuse potential of duloxetine was evaluated in monkeys and rats. Duloxetine did not demonstrate cross physical dependence potential with barbital or physical dependence-producing potential, or any reinforcing effects. The results from studies specifically designed to examine abuse potential indicate that duloxetine would not be expected to pose a risk for substance abuse.

The enteric coating, HPMCAS, has no evidence of absorption; further, HPMCAS has been widely used in medicinal products for oral use in several countries and therefore would not pose any toxicological concern.

An environmental risk assessment was submitted. Although duloxetine would be regarded as a medium risk for aquatic organisms, a low potential for bioaccumulation is observed. Further, duloxetine is extensively metabolised to metabolites that lack pharmacological activity, and therefore substantive excretion of duloxetine from humans is not expected; thus, duloxetine would not pose an environmental concern.

Discussion on the non-clinical aspects

Extensive documentation concerning nonclinical pharmacology and toxicology of duloxetine has been submitted, as well as for related substances and impurities, and excipients included in the formulation. The data presented by the Applicant has been adequately supported by relevant literature references.

The effectiveness of duloxetine in the treatment of SUI is linked to its inhibition of presynaptic neuronal reuptake of serotonin and norepinephrine in the central nervous system, resulting in elevated levels of serotonin and norepinephrine in the synaptic cleft. This suppresses urinary bladder muscular activity in a cat animal model in a dose-dependent manner, and enhances external urethral sphincter activity through centrally mediated (CNS) mechanism.

Safety pharmacology studies on the cardiovascular system, central nervous system, gastrointestinal system, immune system and the kidney have been performed. At therapeutic range, duloxetine is not expected to pose a risk on CNS, smooth muscle, renal, immune, or gastrointestinal functions, and substance abuse is unlikely.

Duloxetine is well absorbed in all studied species, and is extensively metabolised, especially in the liver.

For the treatment of SUI Duloxetine is contraindicated during pregnancy and lactation.
Duloxetine was not shown to be genotoxic or carcinogenic in the studies performed, but multinucleated cells were seen in the liver in the rat carcinogenicity study a species-specific effect, the clinical relevance of this finding being unknown. These findings are reflected in the SPC.

4. Clinical aspects

Introduction

The pharmacokinetic and pharmacodynamic characteristics of duloxetine have been assessed in healthy subjects, special populations, and patients with either stress urinary incontinence (SUI) or major depressive disorder (MDD). The pharmacokinetic data were available from at least 250 healthy subjects, 12 subjects with end-stage renal disease (ESRD), and 6 subjects with cirrhosis in 19 clinical pharmacology studies and at least 421 patients in four Phase 2 and Phase 3 clinical trials. Nearly half of the subjects (45%) in the clinical pharmacology studies were women.

Pharmacokinetics

The pharmacokinetics of duloxetine have been characterised in healthy men and women over a single-dose range of 20 mg to 60 mg and over a multiple-dose range of 40 mg/day to 160 mg/day. For the majority of the studies, duloxetine concentrations were determined using validated high performance liquid chromatography tandem mass spectrometry (HPLC/MS/MS) methods. The assay was validated over the concentrations range of 0.5 ng/mL to 100 ng/mL with higher concentrations obtained after dilution of the samples. In some studies, the two major metabolites of duloxetine - the glucuronide conjugate of 4-hydroxy duloxetine and the sulfate conjugate of 5-hydroxy, 6-methoxy duloxetine - were determined. The metabolite concentrations were obtained using a validated HPLC/MS/MS method over the concentration range of 1 ng/mL to 1000 ng/mL. The overall relative standard deviation (a measure of precision) and absolute relative error (a measure of accuracy) were less than 10% for both assays. Duloxetine and its two major metabolites were found to be stable in plasma stored frozen for the length of time that the study samples were stored under similar conditions.

• Absorption – Bioavailability

Results from mass balance studies indicate a fairly high extent of absorption (>70%) of duloxetine. Duloxetine is a delayed release formulation (capsules containing enteric-coated pellets), and as a result, T\text{max} occurs rather late, at about 6 hours. The absolute oral bioavailability was estimated to a mean of 50%, but individual results ranged between 32 and 80%. Bioequivalence between the clinical trial and the marketing formulations of duloxetine was demonstrated using a 60 mg dose, i.e. not the dose or strength intended for marketing (40 mg). This is acceptable, since all strengths of the final formulation contain the same enteric-coated pellets. When administered with a high-fat meal, there was a 6% decrease in C\text{max} and an 11% decrease in AUC\text{0-\infty}. The absorption was delayed by food, with an increase in T\text{max} of about 4 hours. A specific dose recommendation with respect to food intake is not considered warranted based on this.

• Distribution

Duloxetine has an extensive tissue distribution and is highly bound to plasma proteins. Different figures have been reported, but the degree of binding was generally above 95%. Duloxetine is bound both to albumin and to \(\alpha\)-acid glycoprotein (AAGP). Since AAGP is a protein with variable plasma concentrations, within and between patients, e.g. due to disease states like infections, this could be a source of variability in the pharmacokinetics of duloxetine.

The urinary metabolites of duloxetine were moderately bound to plasma proteins and this binding was unaffected by the presence of duloxetine. Protein binding is not affected by end-stage renal disease (ESRD) or by hepatic impairment, and is independent of duloxetine concentration.
• Elimination

Duloxetine is predominantly eliminated in the urine after undergoing extensive metabolism to numerous metabolites that are pharmacologically inactive. Comparison of the metabolite-to-parent ratio values after IV and oral duloxetine reveal that a larger fraction of the drug is metabolised upon oral administration, likely reflecting first-pass metabolism. The major biotransformation pathways involve oxidation in the naphthyl ring, followed by further oxidation, methylation, and conjugation. The two major circulating metabolites of duloxetine are the glucuronide conjugate of 4-hydroxy duloxetine and the sulfate conjugate of 5-hydroxy, 6-methoxy duloxetine. The cytochrome P450 isoenzymes involved in the oxidative metabolism of duloxetine seem to be CYP1A2 and CYP2D6 based on in vitro and in vivo data. Both CYP1A2 and CYP2D6 were identified as participants in the hydroxylation at 4 and 5 positions, the two dominant routes of duloxetine metabolism. Should the activity of one of CYP1A2 and CYP2D6 be absent or decreased in a subject, the other enzyme would be available to metabolise duloxetine. No unchanged duloxetine is excreted in urine. In vitro studies indicate that neither of these metabolites contributes to the pharmacologic activity of duloxetine.

Hepatic impairment results in a decrease in the formation of the metabolites, which leads to higher plasma concentrations of duloxetine. In contrast, renal impairment (end stage renal disease treated with chronic haemodialysis) reduces their rate of elimination as evidenced by the longer t½ values of the metabolites.

• Dose proportionality and time dependencies

Dose proportionality has been assessed in several studies over a dose range covering the proposed dosage for Ariclaim (80 mg/day). These analyses suggest that higher duloxetine doses are associated with slightly lower CL/F and, correspondingly, the average steady-state concentrations at higher doses are slightly higher than would be projected for a dose-proportional increase. Nevertheless, the magnitude of the deviation from either strictly linear pharmacokinetic behaviour or dose-proportional increases across dose is small, particularly in comparison to the degree of interindividual variability in plasma concentrations. Most importantly, within any individual subject, the deviations from classical linearity or dose-proportionality appear to be very small in magnitude. Thus, the apparent slight non-linear behaviour and more-than-proportional increase in plasma concentration across the duloxetine dosage range of 40 mg/day to 120 mg/day are unlikely to be clinically important. Steady state is generally reached within 3-5 days.

• Special populations

Hepatic impairment: a study using a single low (20 mg) dose was used to study the effect of moderate (Child-Pugh Class B) hepatic cirrhosis on the pharmacokinetics of duloxetine and the major metabolites. However, the pharmacokinetics of duloxetine and its metabolites were not studied in patients with mild or severe hepatic insufficiency. A clear effect was observed after the single dose, with an almost 5-fold increase in AUC<sub>0-∞</sub> and a 3-fold longer T½ of duloxetine. The mean plasma protein binding was lower in the hepatically impaired subjects (not statistically significant, though), indicating an even larger difference in mean unbound exposure. The subjects included had moderate cirrhosis, according the Child-Pugh classification, with scores of 7 or 8. Thus, there is an effect of hepatic disease on the pharmacokinetics of duloxetine even at a quite moderate degree of severity. The SPC specifies that duloxetine should not be used in patients with liver disease resulting in hepatic impairment.

Renal impairment: Pharmacokinetic data on duloxetine is limited in patients with mild or moderate renal impairment. There seems to be no correlation between CLcr and duloxetine CL/F in patients with no renal impairment and mild and moderate renal impairment. Pharmacokinetic data in patients with mild and moderate renal impairment were obtained from Phase III population pharmacokinetic studies. A doubled exposure to duloxetine and several-fold increases in exposure of the inactive metabolites was observed in patients with severe renal impairment, but this patient group is unlikely to experience SUI.
Despite the fact that duloxetine is not renally eliminated, there was a substantial effect on duloxetine pharmacokinetics with a doubled exposure of duloxetine and a 2 to 9-fold increase for the two major metabolites. Based on these considerations no dose adjustment is necessary for patients with mild or moderate renal dysfunction, and as such that is noted in the SPC.

**Age:** pharmacokinetic differences have been identified between younger and elderly females (≥65 years) (AUC increases by about 25% and half-life is about 25% longer in the elderly), although the magnitude of these changes is not sufficient to justify adjustments to the dose.

**Gender:** gender has an effect on the pharmacokinetics of duloxetine, with females having approximately twice as high exposure compared with males. However, many pharmacokinetic studies were performed in males and the results may, thus, not be immediately extrapolated to females. It is agreed that the isoenzymes involved in the metabolism of duloxetine, i.e. CYPs 1A2 and 2D6 are not sex-specific. Bearing this in mind, it cannot be excluded that a different effect of duloxetine on a CYP1A2 substrate would be observed in females as compared to males. A study investigating the effect of duloxetine on the pharmacokinetics of a CYP1A2 substrate, e.g. theophylline, is to be performed also in females.

**Interaction studies**

In vitro data show that CYP2D6 has been shown to be non-inducible and that duloxetine may inhibit CYP3A, CYP1A2, or CYP2C9 at concentrations substantially higher than those anticipated in the clinical setting. It is unlikely that enzyme induction would occur clinically. In vivo drug-drug interaction studies have been carried out with CYP2D6 substrates (desipramine and tolterodine), CYP2D6 inhibitors (paroxetine), CYP1A2 substrates (theophylline), CYP1A2 inhibitors (fluvoxamine), and other drugs and substances likely to be co-administered with duloxetine (lorazepam, temazepam, ethanol and antacids). Duloxetine has shown to be a moderate CYP2D6 inhibitor (3-fold increase in the overall exposure to desipramine and 2-fold increase to tolterodine). Similarly, paroxetine (CYP2D6 inhibitor) increases duloxetine overall exposure by 60%. Fluvoxamine, a potent CYP1A2 inhibitor, increases the exposure of duloxetine (more than 5-fold). No significant interactions with benzodiazepines and antacids have been found. The SPC clearly reflect these findings.

Additional data for CYP2C19 was submitted for this application. It is agreed that these isoforms represent a small part of the metabolism of commonly prescribed drug. However, CYP2C8 is an isoenzyme that has recently gained more interest because of the occurrence of clinically important interactions due to inhibition of this enzyme, e.g. by gemfibrozil. An *in vitro* study investigating the effect of duloxetine on the metabolism of a CYP2C8 substrate is to be performed.

**Conclusion on human pharmacokinetics**

Duloxetine is a drug with highly variable pharmacokinetics and many factors affect the systemic exposure. From the presented data, gender, age, renal and hepatic function, smoking status, CYP2D6 status and drug-drug interactions are all factors affecting the plasma levels of duloxetine. Interindividual differences in plasma concentrations of α1-acid glycoprotein (AAGP) may also contribute to the variability.

Based on the large inter-individual pharmacokinetic variability and the frequency of adverse events, the most common reason for discontinuation of treatment in clinical studies, the possibility to reduce the dose to 20 mg b.i.d. after 4 weeks in case of troublesome adverse events has been introduced.

**Pharmacodynamics**

Six studies were designed to evaluate pharmacodynamics in healthy volunteers. Four of them were aimed to assess pharmacodynamic effects and safety during treatment with increasing doses of duloxetine and the other two evaluated pharmacodynamic interactions with ethanol and lorazepam. In addition the results of Study SBAB assessing the biomechanical effects of 80-mg dose of duloxetine for four weeks versus placebo on bladder and urethral function, was used to elucidate the mechanism of action.
• Mechanism of action

*In vitro*, duloxetine is a potent inhibitor of both 5-HT and NE reuptake and a relatively weak inhibitor of dopamine reuptake. Duloxetine has a low affinity for muscarinic acetylcholine, histamine-1, α-1-NE, 5-HT1A, 5-HT1B, 5HT1D, D2 and opioid receptors. The molecule was active in urinary models indicative of enhancement of serotonin and norepinephrine neurotransmission with improvement of capacity of the urinary bladder and increased urinary sphincter activity. Indirect evidence of similar activity in humans has been obtained. Changes in whole-blood 5-HT concentration following chronic administration of 20-mg or larger daily doses of duloxetine suggest that duloxetine interferes with 5-HT reuptake in humans. Measurement of 48-hour urinary excretion of NE and its metabolites showed that regimens of duloxetine 80 mg once daily or duloxetine 60 mg twice daily were associated with a significant decrease in whole body NE turnover.

Study SBAB assessed the biomechanical effects of 80-mg dose of duloxetine for four weeks versus placebo on bladder and urethral function. Sixty-five (65) women with pure genuine stress incontinence were enrolled in the study. However, only 10 patients on Ariclaim and 11 on placebo were possible to evaluate. After four weeks duloxetine-treated patients experienced a significantly greater median percent reduction of IEF than placebo patients (57.2% compared with 26.3%, p = .024). However, the decrease in the absolute number of episodes per week was not statistically significant (mean of 11.8 with duloxetine compared with 9.1 with placebo).

Urethral function during the filling phase of the micturition and bladder function and sphincter resistance during emptying phase was measured. Although women exhibited a severe urinary incontinence (mean baseline > 21 episodes/week) and pharmacodynamic changes could be expected in a more clear way than in a less severe population, none of the pre-specified analyses comparing duloxetine with placebo revealed statistically significant differences for any of the five biomechanical measures of urethral function measured in the study. Post-hoc analysis of Valsalva leak-point pressure data and an examination of quantitative striated sphincter electromyographic data in the small number of subjects who completed this study did provide some limited evidence to the view that duloxetine to some degree exerts an effect on the urethra.

The data provided by the Study SBAB assessing the biomechanical effects of 80-mg dose of duloxetine do not allow valid conclusions regarding its mechanism of action. This is reflected in the SPC. The unreliability of the PD data does not necessarily preclude a positive benefit/risk conclusion, but this would mostly depend on pure efficacy and safety data. However, a proper knowledge of the mechanism of action of a drug intended for chronic use and with other potential therapeutic indications is considered relevant. Therefore, the Applicant is to perform additional studies in order to further elucidate the mechanism of action of duloxetine in patients with SUI. This is a relevant issue, mainly due to the novel mechanism of action attributed to duloxetine without any other product of reference available for this condition at present.

• Primary and Secondary pharmacology

In the first human study with duloxetine (Study HMAA), a 90% inhibition of ex vivo platelet serotonin uptake was found 2 to 3 hours after the 60-mg doses of up to 60 mg of an immediate-release formulation of duloxetine.

In Study HMAB, 6 subjects received single doses up to 80 mg. Inhibition of ex vivo platelet serotonin uptake were found with all doses tested. Eight hours after dosing, 10 mg produced 35% to 61% inhibition, 20 mg produced 49% to 75% inhibition, 40 mg produced 64% to 92% inhibition, 60 mg produced 70% to 88% inhibition, and 80 mg produced 84% to 92% inhibition.

Other studies aimed to demonstrate significant increase in bladder capacity when comparing duloxetine with placebo. Increase in urethral closure pressures was also evaluated in the same manner. The different founded however was not statistically significant, an the magnitude of such effects is of uncertain relevance when trying to predict a relevant therapeutic effect.

Potential secondary pharmacologic reactions of duloxetine at the clinical dose were noted in the anaesthetised dog model and included increases in pulmonary pressure, pulmonary vascular resistance, and respiratory rate. These effects are attributable to the known actions of norepinephrine and
serotonin and are not likely to pose a clinical risk. There were also no substantive cardiovascular liabilities identified.

As other drugs that inhibit monoamine reuptake, duloxetine significantly increases systolic and diastolic blood pressure (less than 2 mmHg) and heart rate (2 to 3 beats per minute). This can be considered as a class effect and no major safety concern seems to derive from this observation. The effects of duloxetine on QT interval have been assessed in about 160 subjects. There is no signal indicating that duloxetine might prolong the QT interval regardless of the correction method used.

**Clinical efficacy**

The clinical program was developed to assess the efficacy and safety of Duloxetine in female patients with SUI. One Phase II study (study SAAW) and three Phase III studies (studies SBAT, SBAV and SBAX) were conducted. In addition, Phase III studies were extended evaluating safety with long-term exposure to form studies SBAU, SBAW and SBBM respectively. Study SBAY is a stand alone open-label safety study. These studies are summarised in the following table.

<table>
<thead>
<tr>
<th>Study Country)</th>
<th>Phase</th>
<th>Design</th>
<th>Treatment Groups</th>
<th>Duration of Treatment</th>
<th>Number of Patients</th>
<th>Of Safety</th>
<th>I-E</th>
<th>I-QOL</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>(USA)</td>
<td>II</td>
<td>ra, db, pc, fd, pg, mc</td>
<td>Placebo D 20 mg D 40 mg D 80 mg</td>
<td>12 weeks</td>
<td>138</td>
<td>96 %</td>
<td>96%</td>
<td>96%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>138</td>
<td>88 %</td>
<td>93%</td>
<td>93%</td>
<td></td>
</tr>
<tr>
<td>(USA, Canada)</td>
<td>III</td>
<td>ra, db, pc, fd, pg, mc, str</td>
<td>Placebo D 80 mg</td>
<td>12 weeks</td>
<td>247</td>
<td>98 %</td>
<td>99%</td>
<td>98%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>247</td>
<td>86 %</td>
<td>97%</td>
<td>97%</td>
<td></td>
</tr>
<tr>
<td>(USA, Canada)</td>
<td>III</td>
<td>ra, db, pc, fd, pg, mc, str</td>
<td>Placebo D 80 mg</td>
<td>12 weeks</td>
<td>339</td>
<td>95 %</td>
<td>98%</td>
<td>98%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>344</td>
<td>83 %</td>
<td>97%</td>
<td>97%</td>
<td></td>
</tr>
<tr>
<td>(Australia, USA, SAf, SAm, EU)</td>
<td>III</td>
<td>ra, db, pc, fd, pg, mc, str</td>
<td>Placebo D 80 mg</td>
<td>12 weeks</td>
<td>231</td>
<td>99 %</td>
<td>99%</td>
<td>99%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>227</td>
<td>88 %</td>
<td>97%</td>
<td>97%</td>
<td></td>
</tr>
<tr>
<td>(EU, Canada)</td>
<td>III</td>
<td>nr, o, nc, fd, mc</td>
<td>D 80 mg</td>
<td>Ongoing</td>
<td>363 (^a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(USA, Canada)</td>
<td>III</td>
<td>nr, o, nc, fd, mc</td>
<td>D 80 mg</td>
<td>Ongoing</td>
<td>493 (^a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Medicinal product no longer authorised
### Study Design and Treatment Groups

<table>
<thead>
<tr>
<th>Study Country</th>
<th>Phase</th>
<th>Design</th>
<th>Treatment Groups</th>
<th>Duration of Treatmen</th>
<th>Number of Patients</th>
<th>Of Safety</th>
<th>IEF</th>
<th>I-QOL</th>
<th>PGI-I</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Australia, SAf, SAm, EU)</td>
<td>III</td>
<td>nr, o, nc, fd, mc</td>
<td>D 80 mg</td>
<td>Ongoing</td>
<td>334&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(USA)</td>
<td>III</td>
<td>nr, o, nc, fd, mc</td>
<td>D 80 mg</td>
<td>Ongoing</td>
<td>662&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> As of 14 June 2002.

### Dose response study

After an initial study failing to show differences between Duloxetine (20, 30 and 40 mg), the dose finding data package of this dossier is based on one single placebo-controlled trial (Study SAAW). Study SAAW was a randomised, parallel, double blind placebo controlled trial, where 3 doses of Duloxetine (20, 40 and 80 mg) were tested. After a 4-week pre-treatment phase that included a 2-week blinded placebo lead-in, patients were given either placebo or one of the 3 dose levels of Duloxetine (10 mg BID, 20 mg BID or 40 mg BID). The follow-up period on double blind therapy lasted 12 weeks. Patients on Duloxetine 80 mg were dose escalated over two weeks at the initiation of therapy and also de-escalated over two weeks at the end of the 12-week treatment period. As compared with phase III pivotal studies, study SAAW included a population with a slightly lower incontinence episode frequency (IEF) threshold at entry. Study SAAW excluded subjects over 65 years of age and those with prior continence surgery.

The primary efficacy variable was weekly incontinence episode frequency at week 12 based on the ITT population, using the LOCF method. The number of incontinent episodes per 24 hours is a subject-recorded count of the number of incontinent episodes during a 7-day period, obtained from the subject diary. A number of secondary measures were also assessed, including disease-specific tests: cough stress test (CST) and stress pad test (SPT), assessment of the severity of the disease: stress incontinence visual analog scale (SIVAS) and incontinence severity index (ISI), and different measures of QoL and daily life activities. In addition, the Patient Global Impression-Improvement (PGI-I), and the Clinical Global Impression Improvement (CGI-I) at Weeks 4 and 8, and Week 12 were also assessed.

A responder analysis was also carried out for different variables including the main efficacy endpoint. For this purpose, a responder was defined as a patient who had at least a 50% decrease in IEF from baseline to endpoint.

All efficacy evaluations were performed according to an intent-to-treat analysis, defined as patients who were randomized to duloxetine or placebo and who had baseline efficacy data and any post-baseline efficacy data. Questionnaire responses were treated as continuous variables. Analysis of variance (ANOVA) models were used to evaluate continuous efficacy variables. The ANOVA model included terms for treatment, site (as a fixed effect), and treatment-by-site interaction. Pairwise comparisons were analysed with the least squares means (LSMEANS) from the appropriate ANOVA model. Categorical variables were analysed using Pearson’s Chi-square tests. All statistical tests were performed as two-sided, at a .050 significance level except where noted. The analysis of covariance (ANCOVA) models was also used to evaluate efficacy on original and transformed scale.
In order to assess prospectively the accuracy of history, examination, simple bladder filling and stress pad test for the diagnosis of genuine stress incontinence (GSI), provocative subtracted electronic cystometry (PSEC) was performed on 90 women at eight sites. This urodynamic test was employed to determine the proportion of subjects in the study population with GSI, as well as identifying a subset of the patients with GSI who have intrinsic sphincteric deficiency (ISD). Urodynamic traces were centrally read.

Five hundred fifty three patients were enrolled to provide power of 80% to detect a 20% difference in the IEF, assuming a placebo response reduction of 30%.

Duloxetine at 40 and 80 mg/day doses was superior to placebo in decreasing the IEF per week. Statistically significant differences were observed for the percent change from baseline to endpoint in IEF per week for the Duloxetine 40 (adjusted p=.049; unadjusted p=.018) and 80-mg/day (unadjusted p=.045) groups as compared to placebo. The adjusted analysis did not show statistically significant differences between Duloxetine 80 mg and placebo (p = .114). Duloxetine at 40 and 80 mg/day doses was also superior to placebo in decreasing IEF per week when all baseline and post-baseline diaries were pooled. The median percent change from baseline to endpoint in IEF per week was 40% for the placebo group, compared with 59% and 58% for the Duloxetine 40 and 80 mg/day groups, respectively. An analysis of PGI-I ratings and I-QOL questionnaire scores revealed a significant improvement only for the duloxetine 80-mg/day group compared with the placebo group. An analysis of data from subjects who completed the 12-week study did not demonstrate statistically significant differences in the percent change from baseline to endpoint for IEF per week between the placebo group and any of the duloxetine groups.

The responder analysis on the basis of IEF (defined as a reduction ≥ 50% in the number of episodes from baseline) was significantly higher in the Duloxetine 80 mg (60%) group as compared to placebo (47%). 59% of patients on Duloxetine 40 mg were considered as responders (p = .067 vs placebo).

It was considered that, higher plasma concentrations are associated with significantly greater clinical response. Analyses of change in I-QOL scores also demonstrated a significantly greater improvement when the Duloxetine plasma concentrations were higher than the median value (34.8 ng/mL). A significant correlation was observed between Css values and the change in the I-QOL scores (rho = 0.187, p=0.04), indicating that an increase in I-QOL scores is observed when Duloxetine plasma concentrations are higher. A responder analysis for both IEF and I-QOL demonstrated that subjects whose Css values were above the median were significantly more likely respond to Duloxetine therapy in terms of both IEF and QoL (defining response as a ≥ 50% decrease in IEF and an increase in I-QOL of at least 30% of the largest possible increase) than those subjects with C’ss value averages below the median. In the applicant’s view, the PopPK characteristics of Duloxetine support the conclusion that an individual is more likely to maintain a plasma concentration of Duloxetine above a specific critical threshold if she takes 80 mg/day than if she takes only 20 or 40 mg/day. Further, characteristic values for the half-life (averaging approximately 12 hours) and time to peak concentration (averaging approximately 6 hours) predict that concentrations above this threshold level are more likely to be maintained in the early as well as the late hours of the day when administration is twice daily rather than only once daily.

<table>
<thead>
<tr>
<th>Randomized N</th>
<th>Duloxetine 20</th>
<th>Duloxetine 40</th>
<th>Duloxetine 80</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>138</td>
<td>-44.4% (.625)b</td>
<td>-58.6% (.018)b</td>
<td>-57.9% (.045)b</td>
<td>-40.0%</td>
</tr>
<tr>
<td>137</td>
<td>-54.0% (.057)d</td>
<td>-59.2% (.002)d</td>
<td>-63.7% (.&lt;.001)d</td>
<td>-40.7%</td>
</tr>
<tr>
<td>140</td>
<td>-54.0% (.057)d</td>
<td>-59.2% (.002)d</td>
<td>-63.7% (.&lt;.001)d</td>
<td>-40.7%</td>
</tr>
<tr>
<td>138</td>
<td>-40.0%</td>
<td>-40.0%</td>
<td>-40.0%</td>
<td>-40.0%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Median IEF changea</th>
<th>PGI-I ratingc</th>
<th>Mean I-QOL change</th>
<th>Mean number voids/day changec</th>
</tr>
</thead>
<tbody>
<tr>
<td>-44.4% (.625)b</td>
<td>31.1% (.440)f</td>
<td>+5.3 (.614)d</td>
<td>-1.0 (.051)d</td>
</tr>
<tr>
<td>-54.0% (.057)d</td>
<td>56.9% (.185)f</td>
<td>+7.8 (.165)d</td>
<td>-1.2 (.003)d</td>
</tr>
<tr>
<td>-57.9% (.045)b</td>
<td>43.8% (.004)f</td>
<td>+9.3 (.026)d</td>
<td>-1.4 (&lt;.001)d</td>
</tr>
<tr>
<td>-63.7% (.&lt;.001)d</td>
<td>27.3%</td>
<td>+5.8</td>
<td>-0.6</td>
</tr>
</tbody>
</table>

a Using last visit diary analysis. b Significance (p) versus placebo using ANOVA with treatment and site as effects but without controlling for multiple analyses; when controlled for multiple analyses p=.114 for Duloxetine 80 mg.

Using pooled diary analysis. d Significance (p) versus placebo using ANOVA with treatment and site as effects.

c Percent in “Very Much Better” or “Much Better” categories at endpoint. f Significance (p) versus placebo using Cochran-Mantel-Haenszel Test
The safety profile of Duloxetine exhibited in this study is fully consistent with the known safety profile of other agents that inhibit monoamine reuptake. Nausea was the most common AE and was experienced by 13% of women at the 80-mg/day dose. Twelve of 18 women who experienced nausea at the 80-mg/day dose continued medication despite this adverse event. Fatigue, and insomnia were the most clinically relevant dose-dependent AEs; however, these events were not considered to have long-term safety consequences. The Applicant considered that the safety and tolerability of the 40 and 80 mg/day doses are comparable and are not a determining factor for limiting the dose. Based on the overall analysis of the safety and efficacy data, the 80 mg/day dose of Duloxetine was the selected dose for being further assessed.

Study SAAW enrolled a slightly different population than one supposed to be the real target population. Thus, as compared with phase III pivotal studies, study SAAW included patients with a lower incontinence episode frequency (IEF) threshold at entry and excluded subjects over 65 years of age. These selection criteria, although should not have a major impact when extrapolating the efficacy results to the intended target population, might have been a relevant conditioning factor for the high placebo response rate observed in this study. The observed placebo response with regard the primary outcome of the study (IEF) was about 40%, when the expected reduction rate was 25%. This fact has resulted in a clearly underpowered study, where the p values for the finally selected dose are just neighbouring the statistical significance threshold.

The observed effect of Duloxetine (40 and 80 mg) on the IEF reduction from baseline is about 60%, which can be considered a modest effect when considering that placebo reduces the IEF by 40%. In addition, and despite of this 20% difference in the percentage o reduction of IEF, when translating this effect into the median absolute number of SUI episodes per week saved for each patient, Duloxetine 80 mg saves just 1 more episode per day than placebo does (D 80 mg from 7 at baseline to 3 at endpoint vs. PBO from 7 at baseline to 4 at endpoint). This and the effects on I-QOL and other subjective outcomes (PGI-I and CGI-I) could be regarded as a marginal effect.

Main studies

Three studies (Studies SBAT, SBAV, and SBAX) with identical main protocols are the Phase 3 studies that form the basis for efficacy of duloxetine. These studies have the same duloxetine dose (40 mg twice daily), same duration of double blind treatment (12 weeks), and determined subject eligibility based on the same clinical algorithm. Additionally, all three used the same two primary efficacy endpoints and were performed in the target population.

The three studies included 1,635 women with signs of SUI. They were aimed to assess the efficacy of duloxetine 40 mg twice daily versus placebo in the treatment of women with stress urinary incontinence. All of these studies followed a randomised, placebo-controlled, multi-centre, fixed-dose, double blind, parallel-group design, and 12-week comparison study. In all studies, there was a 4-week baseline period with subjects receiving no study drug for two weeks and placebo for last two weeks. After that, patients were randomised to duloxetine 80 mg/day given as 40 mg twice daily (BID) or placebo for 12-weeks.
Methods

Study Participants

All studies enrolled women, 18 years or older, with a stress urinary incontinence of more than 3 months.

Stress urinary incontinence was defined by a clinical algorithm that included a predominant symptom of SUI, with a weekly IEF \( \geq 7 \), absence of predominant symptoms of urge incontinence, normal diurnal and nocturnal frequencies, a bladder capacity of at least 400 mL, and both a positive cough stress test (CST) and stress pad test (SPT) at a bladder volume of 400 mL.

Studies SBAT, and SBAV had addenda that specified urodynamic testing after randomisation for subjects at some study centres. The primary objective of the addendum was to evaluate the ability of the main study’s inclusion and exclusion criteria to define a population of subjects with urodynamic (genuine) stress incontinence. This algorithm was 83%, and 100% specific for urodynamic stress incontinence in subsets of subjects in Studies SBAV, and SBAT, respectively, and assured that the majority of women in the trials, in fact, had SUI. The individual study reports for those studies, which included urodynamics, documented that the algorithm was concordant with urodynamic (genuine) stress incontinence in 83% (Study SBAV), and 100% (Study SBAT) of subjects who had urodynamic testing.

To prevent potential imbalance at baseline in both treatment assignment and incontinence severity, a stratified randomisation was used. At Visit 3, subjects within each site were stratified based on their incontinence episode frequency severity (<14 and \( \geq 14 \) IEF per week). The calculation of severity was made from all the diary records collected after Visit 1 and prior to Visit 3.

Patients with significant uncontrolled comorbidity, any condition of the genitourinary tract, recent continence surgery within 6 months), the current use of a continence device, or treatment with an antidepressant, drugs for obesity, or a medication for incontinence were excluded. Subjects who were on a stable PFMT program for at least 3 months were enrolled as long as they agreed to continue on their PFMT regimen at the same intensity throughout the study.

Treatments

Duloxetine 80 mg/day, given as 40 mg BID or placebo given BID were administered at fixed doses for 12 weeks (visit 3 to visit 6). Subjects were instructed to take their medication twice daily (morning and evening) at consistent times every day.

Outcomes/endpoints

Primary efficacy parameters

- Incontinence Episode Frequency per week (IEF): The IEF was a subject count of the number of incontinence episodes recorded real-time on paper diaries during a 7-day period. The first primary efficacy endpoint was the percent change (as computed by \([\text{Endpoint} - \text{Baseline}] / \text{Baseline}\) in weekly IEF from baseline to endpoint. The diary consisted of seven 24-hour diary records. Only those 24-hour diary records that were deemed to be satisfactory were considered in the efficacy analyses. A satisfactory 24-hour diary record was an account of a calendar date on which the subject recorded the date and time of at least three voids. The 24-hour diary record that had entries on the day of a visit was not considered satisfactory because it could not contain information for a full 24-hour calendar day. At each visit, a single value was produced for each diary variable by taking the mean of all entries from satisfactory diary records (for example, for IEF, mean = total number of incontinence episodes divided by total number of satisfactory diary records) obtained since the previous visit. For IEF, seven to obtain incontinence episode frequency per week multiplied this mean. If less than three satisfactory daily 24-hour diary records were collected, the visit value was considered missing. This way of computing and analyzing the diary variables is referred to as “the last 7-day diary approach.”

- Incontinence Quality of Life (I-QOL): The I-QOL is a validated, disease-specific, 22-item, self-administered questionnaire allowing subjects to evaluate in their native language the effects and
concerns relating to urinary incontinence. The 22 items in the I-QOL can be scored as an overall score or as three domain scores: Avoidance and Limiting Behaviour, Social Embarrassment, and Psychosocial Impact. I-QOL scores and subscale scores are standardized to a scale from 0 to 100, with 100 indicating the best possible condition-specific quality of life. Health status and health-related quality of life measures were used in this study to provide detailed information on the impact of urinary incontinence on subjects’ day-to-day lives.

The second primary endpoint was the change in I-QOL (as computed by [Endpoint – Baseline]). Changes and percent changes were computed for all randomized subjects with at least one postbaseline and one baseline visit measurement using a last observation carried forward approach.

Secondary efficacy parameters
- Patient Global Impression of Improvement (PGI-I): PGI-I is a validated, single-item treatment outcome questionnaire, measuring a subject’s self-perceived improvement since she started taking the study medication. It is measured on a 7-point scale from “Very much better” to “Very much worse”.
- Mean Time Between Voids (MTBV): The MTBV is the average voiding interval derived from the same urinary diaries as defined a priori in the statistical analysis plans for the Phase 3 studies.

Sample size
The sample size provided approximately 80% (SBAT, SBAX)-90% (SBAV) power for detecting a treatment difference of 20% in the median percent change in IEF from baseline to endpoint using a two-sided, .05 level van Elteren test.

The sample size also provided approximately 94% (SBAT, SBAX)-98% (SBAV) power for detecting a treatment difference of 3.5 points in the mean change in I-QOL from baseline to endpoint using a two-sided, .05 level t-test, assuming a standard deviation of 9.9.

This calculation assumed that, 10% or fewer of the randomized subjects would drop out without providing any postbaseline measurement.

Randomisation
Randomization was controlled by a computerized voice response system at a central location for all study sites. The investigator called the voice response system at each visit in order to receive instructions for distributing study medication and/or diary data collection.

Blinding
Conventional methods have been used to ascertain blinding of patients and investigators.

Statistical methods
The primary time point for all efficacy variables was the last visit after randomization at which the variable was obtained. For IEF, this was specified “the last 7-day diary analysis” in contrast to a secondary analysis that compared all pre-randomization diaries to all post-randomization diaries, “the pooled diary analysis.”

Primary statistical analyses were performed according to intent-to-treat (ITT) principles and included all subjects with a baseline and a postbaseline measurement. A secondary completer analysis was also performed to assess the impact of early discontinuations due to adverse events on the efficacy profile of duloxetine. If adverse events and clinical benefits were linked, including discontinued subjects in the ITT analysis could bias the overall results in favour of duloxetine. Therefore, a comparison of ITT and completer analyses results for important outcome variables was critical to assess this potential bias.

For the three Phase 3 trials, the primary analyses for median percent changes in IEF and mean changes in I-QOL score compared duloxetine 40 mg twice daily with placebo using with the following two models:
- Because the normality assumption was not satisfied (Shapiro-Wilks, .01), van Elteren test (van Elteren 1960; a type of stratified Wilcoxon test) was used for analysis of percent change in IEF between the last prerandomisation and last postrandomisation visit diaries with baseline incontinence
severity strata (<14 and ≥14 IEF per week from Visit 1 to randomisation visit) as the stratification variables.

- Changes in I-QOL total scores were analysed using an analysis of covariance (ANCOVA) model. The dependent variables were the change scores, and the model included terms for baseline scores, treatment, baseline incontinence severity strata, and study.

The van Elteren test was also used to analyse other IEF analyses including absolute change scores and pooled analyses (comparing all prerandomisation to all postrandomisation diaries). ANCOVA was also used to analyse changes in I-QOL subscales and mean time between void. Treatment differences in PGI-I responses were tested using the Cochran-Mantel-Haenszel statistic. Efficacy was also analysed by grouping subjects into responders and nonresponders based on relative improvement from baseline in IEF and I-QOL. For IEF, a responder was defined a priori as a subject who had at least a 50% decrease from baseline to endpoint. An I-QOL responder was defined a priori as a subject who improved by at least 30% of the greatest possible improvement in score from baseline to endpoint. The validation of the PGI-I scale with I-QOL improvements suggests that the definition is reasonable. In this validation, subjects who rated themselves "A Little Better" had a 6.4-point increase in their I-QOL scores, while those who rated themselves "Much Better" had a 13.0-point increase. These increases are comparable to the 10.8-point increase that would represent 30% of the maximum possible increase in I-QOL score in the overall integrated database.

Results

**Study SBAT**

**Participant flow**

![Flowchart](image)

**Recruitment**

The recruitment period for study SBAT comprised from December 7th 2000 to March 4th 2002
Conduct of the study

The studies were conducted according to GCP principles and the ethical principles as stated in the Declaration of Helsinki.

Baseline data

No significant baseline differences between groups in the individual studies were found for IEF, I-QOL, urine loss in Stress Pad Test, Patient Global Impression - Severity, number of micturitions per day, and nocturia.

The groups seem to be representative regarding age, BMI and menopausal status. More than half of the non-menstruating patients used HRT, which is a high figure. The significant difference in age in study SBAT is probably of no clinical importance. The importance of the lower alcohol consumption in the duloxetine groups is difficult to judge. The dominance of Caucasian women limits the possibility to conclude on efficacy in other ethnic groups.

Summary of demographic and other baseline characteristics : % or mean (range)

<table>
<thead>
<tr>
<th>SBAT Placebo</th>
<th>SBAT Duloxetine</th>
<th>SBAV Placebo</th>
<th>SBAV Duloxetine</th>
<th>SBAX Placebo</th>
<th>SBAX Duloxetine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>54 (28-82)</td>
<td>52 * (24-76)</td>
<td>53 (24-83)</td>
<td>52 (23-81)</td>
<td>53 (27-77)</td>
</tr>
<tr>
<td>BMI</td>
<td>27 (18-47)</td>
<td>27 (18-56)</td>
<td>29 (18-61)</td>
<td>29 (18-76)</td>
<td>28 (18-48)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>97.6</td>
<td>98.8</td>
<td>90.9</td>
<td>88.7</td>
<td>93.5</td>
</tr>
<tr>
<td>Menstruating</td>
<td>31</td>
<td>34</td>
<td>40</td>
<td>39</td>
<td>34</td>
</tr>
<tr>
<td>On HRT</td>
<td>33</td>
<td>32</td>
<td>44</td>
<td>45</td>
<td>35</td>
</tr>
<tr>
<td>On PFMT</td>
<td>19</td>
<td>19</td>
<td>18</td>
<td>17</td>
<td>12</td>
</tr>
<tr>
<td>Previous surgery</td>
<td>8</td>
<td>8</td>
<td>11</td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td>Consuming alcohol</td>
<td>85</td>
<td>77*</td>
<td>60</td>
<td>50 *</td>
<td>66</td>
</tr>
<tr>
<td>Alcohol Units/week</td>
<td>4 (0-20)</td>
<td>3 (0-20)*</td>
<td>1.9 (0-15)</td>
<td>1.6 (0-18)</td>
<td>1.4 (0-34)</td>
</tr>
</tbody>
</table>

* difference between groups, p<0.05.

Numbers analysed

Study SBAT enrolled 494 patients (247 to placebo and 247 to duloxetine), of which, at 12-weeks, 8.5% (21 patients) discontinued in placebo group and 27.5% (68 patients) in duloxetine. Insufficient therapeutic effect led to a premature discontinuation in 0.8% of placebo group and 2.4% in duloxetine. Adverse events led to a premature discontinuation in 4.9% of the placebo group and 21.5% in duloxetine group. For the IEF analysis, 35 subjects were excluded from the duloxetine group and 5 from the placebo group because they had no post-baseline results for IEF. For the I-QOL analysis, 7 subjects were excluded from the duloxetine group and 2 from the placebo group because they had no post-baseline results for I-QOL.

Outcomes and estimation

The primary objective for IEF but not for I-QOL was met. At 12 weeks (primary analysis) Duloxetine was significantly superior to placebo in decreasing the IEF per week (p=.002). The median decrease was 50.0% in the duloxetine group and 29.3% in the placebo group. However, there was no significant difference between duloxetine and placebo in I-QOL score improvements (5.5 vs. 4.1) When the responder rate was analysed significantly more subjects in the duloxetine than in the placebo group were classified as IEF responders (51.9% vs 33.5%) and I-QOL responders (37.1% vs 27.8%)
Study SBAV

Participant flow

Numbers analysed

Study SBAV enrolled 683 subjects randomly assigned to duloxetine 80 mg/day (n = 344), or placebo (n = 339). Considering causes for discontinuation, adverse events led to discontinuation in 4.1% of patients in placebo group, and 24.1% in duloxetine group. Discontinuation due to insufficient therapeutic effect occurred in 2.4% in placebo group and 0.6% in duloxetine. Premature discontinuation was 30.8% in duloxetine placebo group and 12.7% with placebo. For the IEF analysis, there were 608 patients eligible for the ITT population (without taking into account discontinuations) with 322 in the placebo group and 286 in the duloxetine group. For the I-QOL analysis, 11 subjects were excluded from the duloxetine group and 7 from the placebo group.

Outcomes and estimation

Duloxetine was significantly superior to placebo in decreasing the IEF per week (p<.001). The median decrease was 50.0% in the duloxetine group and 27.5% in the placebo group. I-QOL score increases were significantly greater in duloxetine subjects than in placebo subjects, with mean improvements of 11.01 points in the duloxetine group compared with 6.80 points in the placebo group (p<.001). Significantly more subjects in the duloxetine group than in the placebo group were classified as responders by IEF (51.4% vs 33.5%) and I-QOL (47.7% vs. 35.5%) criteria.

Ancillary analyses

In this study subjects were systematically evaluated for depression according the Beck Depression Inventory–II (BDI-II) at the last baseline visit and at the last treatment visit. Subjects receiving treatment with antidepressants were excluded from the study. Mean BDI-II scores did not differ at baseline between duloxetine- and placebo-treated subjects. Only 23 of 649 (3.5%) subjects had appreciable symptoms of depression based on a BDI-II score of 17 or greater at baseline. This small subset of subjects had somewhat lower I-QOL scores and a somewhat greater number of incontinence episodes at baseline than subjects with lower BDI-II scores. However, the higher BDI-II score...
subgroup did not demonstrate neither a significant reduction in median IEF (duloxetine-placebo difference 10.7%, \( p = .42 \)) nor a significant improvement in total mean I-QOL scores (duloxetine-placebo difference 2.36, \( p = .69 \)), while the lower BDI-II score subgroup did (duloxetine-placebo difference 22.3%, \( p< .001 \) and 4.62, \( p<.001 \), respectively).

**Study SBAX**

**Participant flow**

**Numbers analysed**

In study SBAX 458 subjects were enrolled and randomly assigned to duloxetine 80 mg/day (n =227), or placebo (n =231). Of this, at 12-weeks, 8.2% (19 patients) discontinued in placebo group and 26% (56 patients) discontinued in the duloxetine group. While no premature discontinuation was due to lack of efficacy, adverse events led to a premature discontinuation in 1.7% of the placebo group and 17.2% in the duloxetine group. For the IEF analysis, 27 subjects were excluded from the duloxetine group and 2 from the placebo group because they had no postbaseline results. For the I-QOL analysis, 7 subjects were excluded from the duloxetine group and 2 from the placebo group because they had no postbaseline results.

**Outcomes and estimation**

Duloxetine was superior to placebo in decreasing the IEF per week (\( p= .050 \)) using the last 7-day diary approach.. The median decrease was 53.6% in the duloxetine group and 40.0% in the placebo group. I-QOL score increases were significantly greater for subjects taking duloxetine than for subjects taking placebo, with mean improvements of 10.34 points in the duloxetine group compared with 6.42 points in the placebo group (\( p= .007 \)).

- Analysis performed across trials (pooled analyses and meta-analysis)

The Applicant has carried out a pooled analysis including data derived from four studies (Studies SBAT, SBAX, SBAV, and SAAW) with the same duloxetine dose (40 mg twice daily) and duration of treatment (12 weeks), and that determined subject eligibility based on the same clinical algorithm (except that that Study SAAW had a slightly lower IEF threshold at entry and excluded women over
age 65 years and those with prior continence surgery). Most of the subjects (except in study SAAW) rated their disease severity as moderate or severe.

A total of 1913 subjects were randomised in Studies SAAW, SBAT, SBAV, and SBAX. Of these subjects, 538 (28.1%) were enrolled in Western Europe, 978 (51.1%) in North America, and 397 (20.8%) in Africa, South America, and Australia.

### Condition-Specific Baseline Severity

<table>
<thead>
<tr>
<th>Study</th>
<th>Weekly IEF</th>
<th>Total I-QOL score</th>
<th>PGI-S</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Duloxetine</td>
<td>Placebo</td>
</tr>
<tr>
<td>SBAV</td>
<td>19.0</td>
<td>18.2</td>
<td>64.3</td>
</tr>
<tr>
<td>SBAT</td>
<td>17.2</td>
<td>17.3</td>
<td>64.4</td>
</tr>
<tr>
<td>SBAX</td>
<td>18.3</td>
<td>18.5</td>
<td>58.3</td>
</tr>
<tr>
<td>SAAW</td>
<td>9.3</td>
<td>10.4</td>
<td>72.8</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td>17.0</td>
<td>16.9</td>
<td>64.1</td>
</tr>
</tbody>
</table>

The percent decrease in IEF in the duloxetine 40 mg twice daily group was significantly greater than in the placebo group (duloxetine median 52% [95% confidence interval, 47% to 56%], placebo median 33% [95% confidence interval, 29% to 36%], p<.001) in the ITT analysis. Results on the completer analysis at week 12 are similar to those for the ITT population. There was a greater median decrease in percent change for the duloxetine group at every visit, compared with the placebo group. The following figure shows the results by study.

There were significantly more IEF responders (50% or greater reduction in IEF) in the duloxetine group (53%) than in the placebo group (38%, p<.001) and more than twice as many duloxetine subjects than placebo subjects (228 duloxetine, 108 placebo, p<.0001) were responders at every visit after randomisation. While the number of continuing responders decreased at each visit, the majority of initial duloxetine responders (228/448, 51%) were responders at every visit and 73% (327/448) were responders at a minimum of 2 of the 3 visits in the ITT analysis. Overall, 33.4% of duloxetine-treated subjects were classified as responders at every visit.

When the results were analysed by the predefined severity strata for incontinence, there was no significant response for duloxetine compared with placebo among women with IEF <14 per week (i.e. mild SUI) in 1 of the 3 studies (see table below). However, the clinical relevance of the reduction was marginal.
### IEF/week, pooled diary approach, by baseline incontinence severity (<14, ≥14)

<table>
<thead>
<tr>
<th>Study</th>
<th>Baseline IEF</th>
<th>Treatment (n)</th>
<th>Baseline, mean (SD)</th>
<th>Endpoint, mean (SD)</th>
<th>Percent change, median</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBAT</td>
<td>&lt;14</td>
<td>Placebo (113)</td>
<td>9.6 (2.5)</td>
<td>9.4 (2.5)</td>
<td>6.7 (4.3)</td>
<td>5.8 (4.9)</td>
</tr>
<tr>
<td></td>
<td>≥14</td>
<td>Placebo (129)</td>
<td>27.2 (12.0)</td>
<td>27.5 (11.5)</td>
<td>20.1 (14.1)</td>
<td>14.0 (10.3)</td>
</tr>
<tr>
<td>SBAV</td>
<td>&lt;14</td>
<td>Placebo</td>
<td>9.3 (2.4)</td>
<td>9.4 (2.5)</td>
<td>6.7 (4.6)</td>
<td>4.2 (3.3)</td>
</tr>
<tr>
<td></td>
<td>≥14</td>
<td>Placebo</td>
<td>27.9 (14.3)</td>
<td>27.7 (13.5)</td>
<td>20.0 (14.3)</td>
<td>12.8 (10.4)</td>
</tr>
<tr>
<td>SBAX</td>
<td>&lt;14</td>
<td>Placebo</td>
<td>9.2 (2.6)</td>
<td>9.9 (2.3)</td>
<td>6.0 (5.1)</td>
<td>5.1 (4.0)</td>
</tr>
<tr>
<td></td>
<td>≥14</td>
<td>Placebo</td>
<td>29.0 (15.2)</td>
<td>28.5 (15.1)</td>
<td>18.3 (13.5)</td>
<td>13.7 (12.7)</td>
</tr>
</tbody>
</table>

In the combined database, the duloxetine 40 mg twice-daily group showed significantly greater improvement in I-QOL total scores compared with the placebo group in the ITT analysis (9.2 versus 5.9, p<.001) and the completer analysis (10.4 versus 6.1, p<.001). The following figure shows the results by study. As with the IEF analysis, the effect on I-QOL was less pronounced and not significant in patients with a baseline IEF <14.

- **Discussion on clinical efficacy**

The selection criteria applied in phase III clinical trials identify patients with SUI on the basis of clinical findings (signs and symptoms). A subset of patients underwent urodynamic evaluations indicating that most of enrolled patients were truly suffering from SUI. Exclusion criteria intend to avoid the inclusion of patients with urge incontinence.

Patients enrolled in phase III correspond to a moderate/severe SUI population (according to the PGI rating). Only 16% of the patients were having concurrent pelvic muscle floor training (PFMT), which is considered the first step in the treatment of SUI. However the ever-use and current-use PFMT rates were similar to those reported in the general population, supporting the generalizability of the study populations.

Design of pivotal studies as parallel double blind against placebo, measurement of efficacy at 12 weeks and efficacy parameters are considered appropriated and are, in fact, in agreement with the recommendations made by the CHMP Note for Guidance on the Clinical Investigation of Medicinal Products for the treatment of Urinary Incontinence (CHMP/EWP/18/01)
The Applicant has selected the percentage reduction from baseline in IEF as the primary endpoint, using a quantitative assessment of a disease-specific QoL scale as a supportive primary endpoint. As secondary variables, PGI, CGI (among other variables) and an analysis of responders on the basis of pre-defined cut-off points for the different variables have been also provided. This strategy is not entirely in line with the CHMP Note for Guidance, suggesting that main therapeutic trials should focus the use of measurements of subjective improvement, as the PGI or the CGI. However, and provided that consistency in the drug effect on these variables is proven, the Applicant approach was considered acceptable when taking on board that the mentioned CHMP Note for Guidance came into operation on December 2002 and the present dossier was filed on November 2002.

Overall, although not statistically significant in all trials, duloxetine has shown a consistently greater effect on IEF and QoL than placebo. The magnitude of the relative effect on IEF is about a 50% reduction with considerable placebo response ranging from 27% to 40%. However, and as already highlighted for the dose-finding study, the absolute median reduction in incontinence episode frequency per week was only 1.5, 3.0, and 3.9 for the phase 3 trials compared with placebo. The clinical relevance of such magnitude can be questioned. I-QOL assessment as well as the PGI and the CGI show a consistent effect of duloxetine over placebo.

Only 16% of patients were receiving PFMT during the study and no information is provided on the quality of and compliance with it. PFMT is considered the first therapeutic approach for women with SUI. Published data indicate that this non-pharmacological approach can improve symptoms in around half of patients. In this regard, the clinical development program does not reveal whether duloxetine therapy provides any additional effect to an adequately standardised PFMT.

Study SBAF provides additional information about the role of duloxetine in the moderate-severe SUI therapeutic program where PFMT is considered a first stage step. The primary objective of this study was to compare combined therapy (duloxetine + PFMT) versus no treatment (placebo + imitation PFMT) and to compare combined therapy versus PFMT. Combined therapy showed the greatest IEF reduction than each monotherapy (duloxetine or PFMT) or placebo. Duloxetine alone showed greater reduction than PFMT. Thus, in the assessors’ view, study SBAF would support use of the combined treatment. It could be questioned, however, if the study period of 3 months was long enough to allow the maximum effect of PFMT to be demonstrated. The results would therefore support a recommendation to use the combined treatment. This is reflected in the SPC.

In this type of disease, the clinical relevance of the observed improvement assessed by mean of quantitative (continuous or discrete) variables is of difficult interpretation, and a responder analysis in a prospectively defined way is considered of paramount importance. Upon request, an analysis of the number of "dry" days during treatment in relation to pre-treatment was made to contribute to the interpretation of clinical effects.

When patients were analysed according their incontinence severity at baseline (< 14 IEF/week and ≥ 14 IEF/week) the improvement was less pronounced for the less severe strata of patients without a clear translation into a quality of life benefit. A new analysis of the previously submitted efficacy data was provided according to the number of dry days (from 7 to 0) at the end of the study. Cure rates (i.e. dry 7 days) are really scarce for both stratum (more severe: duloxetine 5.4%, placebo 2.9%; less severe: duloxetine 15.7%, placebo: 12.5%). For the less severe subjects differences between duloxetine and placebo treated patients hardly achieved 6% across the complete distribution of dry days. Thus, the clinical meaningfulness of duloxetine in women with less severe SUI is still questionable.

When a new definition (post-hoc) of cure or improvement was applied (4 or more dry days/week) 58.6% of patients on duloxetine and 52.5% on placebo responded (p=.09; chi-square) within the less severe stratum. Among patients with more than 14 episodes per week the response rate on the basis of the same variable was 27% for duloxetine and 14.7% for placebo.

Although previous surgery, in a pooled data analysis, did not appear to have an impact on duloxetine efficacy with regard to reduction of IEF, the weight of this analysis is considered limited, and this is reflected in the SPC.

Study SBBA compared the of duloxetine80 mg/day with placebo on quality of life in a naturalistic protocol resembling general conditions of clinical practice. The study failed to show any positive effect of duloxetine over placebo on quality of life. No information regarding the number of incontinence episodes at baseline has been provided nor on the reduction in IEF achieved at the end of the treatment. However, less restrictive inclusion criteria considered for this study (≥ 1 incontinence
episode per week) would allow recruiting a population close to the less severe end of the disease. Those negative results seem to confirm the negligible effect of duloxetine in mild SUI patients. On the other hand, when severely affected patients are enrolled (Study SBAM) significantly greater reduction in IEF was achieved in duloxetine treated patients compared with those in placebo group. This was also reflected in I-QOL improvement. The SPC, therefore, clearly reflects the limited usefulness of duloxetine in patients with mild SUI.

It is important to assess the efficacy beyond 3 months. The negative results of the study SBBA, which failed to show positive effect of duloxetine over placebo over a treatment period of 36 weeks in an ordinary clinical setting, throws serious doubts as to the clinical meaningfulness of the product in general long-term use. Thus, the long-term (>3 months) results still remain weak and, considering that SUI is a sustained problem for the majority of women, the lack of documented long-term effects is reflected in the SPC.

Clinical safety

The integrated safety data were classified into three databases based on duloxetine dosage and treatment indications.

The primary safety database includes data on duloxetine- and placebo-treated women from all completed double-blind SUI studies in which subjects were randomly assigned to a dose of 40 mg twice daily throughout the trial. The three Phase 3 randomised clinical trials (Studies SBAT, SBAV, and SBAX), one Phase 2 randomised clinical trial (Study SAAW), the three open-label extensions to the three Phase 3 trials (Studies SBAU, SBAW, and SBBM), and one stand-alone open-label safety study (Study SBAY) comprise the primary safety database.

The secondary safety database includes data from all subjects (women and men) from all completed double-blind depression and pain studies in which subjects were randomly assigned to a dose of at least 40 mg twice-daily duloxetine or to placebo. Also included are data from the final locked database of the long-term, open-label depression study.

The tertiary safety database consists of data from clinical pharmacology studies, all completed urinary incontinence and depression studies in which subjects were randomised to a dose of less than duloxetine 40 mg twice daily or placebo, Japanese studies, and all ongoing duloxetine studies except those in the primary safety database.

Safety data (adverse events, vital signs, and clinical laboratory tests) were monitored throughout the studies. Adverse events were elicited by open-ended, nondirected questioning of the subject, clinical observation, and source document review. The adverse events terms initially recorded by site personnel were mapped to Medical Dictionary for Regulatory Activities (MedDRA) terms. The study site investigator based on his or her clinical judgement assigned causality for SAEs and deaths.

• Patient exposure

A total of 4127 duloxetine subjects, representing approximately 1842 subject-years of exposure to duloxetine, were included in the primary and secondary safety databases up to the data cut-off date of 14 June 2002.

There were 2301 subjects in the primary safety database ranging from 20 to 87 years of age; all were women, and 93% were Caucasian. They had approximately 956 subject-years of exposure, with 190 of those subject-years of exposure occurring in the placebo-controlled trials in patients with SUI (958 duloxetine-treated and 955 placebo-treated patients). Of all the subjects in the primary safety database, 818 had more than 6 months of exposure to duloxetine, and 191 had more than 12 months of exposure.

• Adverse events

Treatment-emergent adverse events (TEAEs) from double-blind trials in the primary safety database for which the incidence in the duloxetine treatment group was ≥5.0% and significantly greater than the incidence in the placebo group were nausea (23.2% vs 3.7%), dry mouth (13.4% vs 1.5%), fatigue (12.7% vs 3.8%), insomnia (12.6% vs 1.9%), constipation (11.0% vs 2.3), headache (9.7% vs 6.6%), dizziness (excluding vertigo) (9.5% vs 2.6%), somnolence (6.8% vs 0.1%), and diarrhoea (5.1% vs 2.7%).

Adverse events reported with a significantly greater frequency in the duloxetine group compared with placebo for which the incidence was <5% and ≥1% were vomiting, increased sweating, anorexia,
dyspepsia, tremor, lethargy, decreased appetite, sleep disorder, anxiety, decreased libido, anorgasmia, pruritus, blurred vision, weakness, nervousness, and thirst. Adverse events reported with a significantly greater frequency in the duloxetine group compared with placebo for which the incidence was < 1% was nocturia, rigors, asthenia, mydriasis, lost of libido, and yawning.

The most common adverse events, except diarrhoea, typically began within the first month of treatment, many within the first 2 days. Most common adverse events resolved in the majority of subjects within 7 to 30 days. Insomnia, dry mouth and constipation tended to be more persistent than other common adverse events.

<table>
<thead>
<tr>
<th>Treatment-Emergent Adverse Events in Order of Decreasing Frequency Within Duloxetine Treatment Group MedDRA Preferred Terms Integrated Controlled Studies – Primary Safety Database, All Randomised Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>(7) TEA Events</td>
</tr>
<tr>
<td>(8) Placebo (n = 955)</td>
</tr>
<tr>
<td>TEA Events (n = 958)</td>
</tr>
<tr>
<td>Fisher exact test</td>
</tr>
<tr>
<td>CMH test</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Dry mouth</td>
</tr>
<tr>
<td>Fatigue</td>
</tr>
<tr>
<td>Insomnia</td>
</tr>
<tr>
<td>Constipation</td>
</tr>
<tr>
<td>Headache NOS</td>
</tr>
<tr>
<td>Dizziness (excl. vertigo)</td>
</tr>
<tr>
<td>Somnolence</td>
</tr>
<tr>
<td>Diarrhoea NOS</td>
</tr>
<tr>
<td>Vomiting NOS</td>
</tr>
<tr>
<td>Sweating increased</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
</tr>
<tr>
<td>Anorexia</td>
</tr>
<tr>
<td>Influenza</td>
</tr>
<tr>
<td>Dyspepsia</td>
</tr>
<tr>
<td>Tremor</td>
</tr>
<tr>
<td>Lethargy</td>
</tr>
<tr>
<td>Appetite decreased NOS</td>
</tr>
<tr>
<td>Sleep disorder NOS</td>
</tr>
<tr>
<td>Sinusitis NOS</td>
</tr>
<tr>
<td>Urinary tract infection NOS</td>
</tr>
<tr>
<td>Anxiety NEC</td>
</tr>
<tr>
<td>Back pain</td>
</tr>
<tr>
<td>Hot flushes NOS</td>
</tr>
<tr>
<td>Hypertension NOS</td>
</tr>
<tr>
<td>Palpitations</td>
</tr>
<tr>
<td>Arthralgia</td>
</tr>
<tr>
<td>Cough</td>
</tr>
<tr>
<td>Libido decreased</td>
</tr>
<tr>
<td>Anorgasmia</td>
</tr>
<tr>
<td>Depression NOS</td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Pruritus NOS</td>
</tr>
<tr>
<td>Abdominal pain upper</td>
</tr>
<tr>
<td>Abdominal pain NOS</td>
</tr>
<tr>
<td>Vertigo</td>
</tr>
<tr>
<td>Vision blurred</td>
</tr>
<tr>
<td>Weakness</td>
</tr>
<tr>
<td>Nervousness</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
</tr>
<tr>
<td>Upper respiratory tract infection NOS</td>
</tr>
<tr>
<td>Bronchitis</td>
</tr>
<tr>
<td>Flatulence</td>
</tr>
<tr>
<td>Myalgia</td>
</tr>
<tr>
<td>Pyrexia</td>
</tr>
<tr>
<td>Rash NOS</td>
</tr>
<tr>
<td>Thirst</td>
</tr>
<tr>
<td>Migraine NOS</td>
</tr>
</tbody>
</table>

* P-value is from Cochran-Mantel-Haenzel Test stratified by study

- **Serious adverse event/deaths/other significant events**

One death (a 70-year-old Caucasian woman, previously diagnosed of hypertension and hypercholesterolemia who had been taking duloxetine for 52 days and suffered a multifocal embolic cerebrovascular accident resulting in coma and death) was reported from the primary safety database. This event was judged by the investigator to be unrelated to study drug. After the database cut-off date of 14 June 2002, a second death occurred in this primary safety database. A 59-year-old woman assigned to duloxetine, died from a pulmonary oat cell metastatic carcinoma. In the opinion of the investigator, it is unlikely it were related to study drug. An autopsy for this subject is pending and further information has been requested.

Two deaths were reported for the controlled studies in the secondary safety database (1 duloxetine, 1 placebo): A 77-year-old Caucasian man randomised to duloxetine 40 mg twice daily, who experienced a cardiopulmonary arrest that resulted in death 4 days after his last dose of duloxetine and was considered not related, and a 73-year-old Caucasian man randomised to placebo treatment who experienced an accidental drowning resulting in death. Six deaths (4 duloxetine, 1 placebo, 1 blinded treatment) were reported in the tertiary safety database before or after data cut-off date, none of them being attributable to study drug or procedures.

When both double blind and open-label studies in the primary safety database were reviewed, 70 subjects (3.2%) had reported a total of 105 SAEs. The majority of SAE in the duloxetine-treated group were not attributed to the study drug by the investigators who were blinded.

The incidence of SAEs that may be related to duloxetine was low. The incidence of SAEs did not differ significantly from placebo.

A recently reported SAR of a completed suicide in a healthy female volunteer without SUI on placebo after being tapered from a high dose of duloxetine reinforces the need for a detailed description of suicides occurring during the clinical development of duloxetine and during its post-marketing experience outside the EU. The risk of discontinuation symptoms are clearly stated in the SPC.

Another case of suicide attempt in a 43 year-old female patient in an open label phase III study was reported during the Decision-making phase. The view of the Committee was that Ariclaim is expected to be prescribed and used by physicians and patients that might be not fully informed of the potential association between antidepressant drugs and suicidal behaviour.

As a consequence, the CHMP considered that the SPC and the PL for all medicinal products containing duloxetine should include information, warning prescribers and patients of this potential risk. This warning was considered especially important for Ariclaim, as it is expected to be used in a population, which might be unaware of this problem.

Appropriate warning information has been included in the SPC and PL. Additionally, a post-marketing surveillance program for all medicinal products containing duloxetine will be carried out.
• Laboratoy findings

Numerically small but significant increases were observed in the mean values for aspartate transaminase, alanine transaminase, and alkaline phosphotase in the duloxetine-treated group compared with the placebo group. Significantly more duloxetine-treated subjects had elevations of ALT and AST above the Covance reference range than placebo-treated subjects. No significant difference was observed between duloxetine- and placebo-treated subjects in the incidence of hepatic enzyme elevations ≥3 times and ≥10 times the upper limit of normal using the Covance reference ranges. No case of previously defined as severe hepatic injury was reported in duloxetine treated subjects.

A mean increase of 5.8 U/L in CPK was observed for duloxetine-treated subjects, compared with 0.1 U/L for the subjects assigned to placebo. Elevated CPK levels were observed at any time after randomisation in 28 duloxetine-treated compared with 27 placebo-treated subjects. A single subject with baseline CPK level within the normal range had a CPK elevation of 4430 U/L 98 days after starting duloxetine. The CPK level drawn one month later was 98.

The blood pressure (BP) increases with duloxetine were small though consistent across all studies in the primary and secondary databases and averaged <2 mmHg. There was no significant difference in the incidence of sustained hypertension (sustained increases of either systolic or diastolic pressures) between the duloxetine-treated (0.2%) and placebo-treated (0.7%) groups in the placebo-controlled trials. The mean increases in systolic and diastolic BPs observed for subjects with pre-existing hypertension assigned to duloxetine were smaller than those observed for subjects assigned to placebo.

Effects of duloxetine on ECG parameters were assessed. Clinical pharmacological studies involving a total of approximately 160 subjects who had received a single 60-mg dose, showed a shorter QTc intervals and a small (4 msec) decrease in the PR interval.

Overall, the QT interval corrected for heart rate (QTc) analysis revealed no arrhythmogenic tendencies with duloxetine. A statistically significant increase in heart rate accompanied by the expected decrease in both PR and RR intervals was observed with duloxetine, consistent with its clinically mild peripheral noradrenergic pharmacologic action. (in both primary controlled and uncontrolled studies)

• Safety in special populations

Safety data were analysed according to subgroups based on age, race, and pre-existing hypertension. There were no clinically relevant interactions in the incidence of adverse events, changes in laboratory values, or in vital signs observed for duloxetine treatment for the age or race subgroups. Significantly more ESRD subjects reported adverse events occurring on or after the only dose of the study drug (8 ESRD subjects reported 17 adverse events), compared with healthy subjects (1 subject reported five adverse events). Subjects with cirrhosis Child Pugh class B experienced more adverse events although there were no serious events in any subject. Each of the 6 cirrhotic subjects reported a total of 35 adverse events (25 possible or probably related) versus no adverse events reported in seven healthy subjects. Nineteen pregnancies exposed to duloxetine at various doses were reported from all three-safety databases. All exposures were in the first trimester. Eleven had pregnancies that delivered in the third trimester, of whom 9 delivered apparently normal babies at term, and 2 delivered after premature rupture of membranes and/or preterm labour, with neither infant surviving.

• Safety related to drug-drug interactions and other interactions

In the double-blind studies in the primary safety database, 86.5% of subjects (duloxetine 86.0%, placebo 86.9%) used one or more of approximately 1140 concomitant medications. Of these, four (ibuprofen, paracetamol, conjugated estrogens, and a multivitamin) were used by 10.3% to 12.2% of subjects. An additional seven (acetylsalicylic acid, various thyroid and reproductive hormones, various vitamins, and calcium) were used by 5% to 10% of subjects. Of the unique medications consumed, 99% did fewer than 30 subjects assigned to duloxetine, and over 96% each use each fewer than 15 subjects assigned to duloxetine used. No analysis of the relationship between concomitant medications and adverse events with duloxetine was performed due to the large number of medications and the small size of the subgroups.

For all of the individual cases of serious adverse events occurring during the duloxetine clinical trials, the responsible investigator assessed the possible causal relationship of concomitant medications administered to the specific subject.
Women using medications in several classes (antidepressants, stimulant drugs used in the treatment of obesity, monoamine oxidase inhibitors [MAOIs], and other incontinence drugs) were excluded from participating in the stress incontinence clinical trials.

- **Discontinuation due to adverse events**
  In the controlled studies (primary safety database), the overall incidence of discontinuation due to adverse events was significantly greater for the duloxetine group (196; 20.5%) compared with the placebo group (37; 3.9%). Specific adverse events for which the discontinuation rate in duloxetine-treated subjects was ≥ 1.0% and twice the rate of placebo-treated subjects were nausea, dizziness (excluding vertigo), insomnia, fatigue, and somnolence. All were significantly more common in duloxetine-treated subjects as well as anxiety (duloxetine 0.6% vs placebo 0%). When long-term open-label extension studies were included, the overall incidence of discontinuation due to duloxetine-associated adverse events was 30.6%. The majority of discontinuations (87%) occurred in the first 4 weeks of duloxetine treatment. The overall incidence of discontinuation due to duloxetine-associated adverse events was 30.6% in the primary safety database (including the four open-label extension studies) up to the database cutoff date of 14 June 2002.

- **Discontinuation symptoms**
  Discontinuation symptoms seen after duloxetine treatment (secondary safety database) reported with a significantly greater frequency by duloxetine-treated subjects included dizziness (excluding vertigo), headache, nausea, paraesthesia, abnormal dreams, nightmare, irritability, somnolence, increased appetite, and tension. The risk of discontinuation symptoms is clearly stated in the SPC.

- **Post marketing experience**
  Duloxetine has not been approved for marketing in any country at this time.

- **Discussion on clinical safety**
  The safety database from short-term trials (12 weeks) is extensive (958 exposed patients) and well reported. Data on long-term exposure have been less extensively reported as they emanate from ongoing studies. 191 patients have been exposed for 12 months in SUI studies. In addition data from the secondary safety database including studies for other indications than SUI have been presented. Forty various AEs occurred significantly more often in the duloxetine group than in the placebo group in the pooled 12-week studies. The most common AEs were nausea (23%), dry mouth (13%), fatigue (13%), insomnia (13%), and constipation (11%). Headache, dizziness, somnolence, and diarrhoea occurred in 5-10% of the duloxetine patients. Another 16 AEs, including vomiting, anorectic disturbances, libido disturbances, sleep disorders, lethargy, and weakness occurred in 1-5% of the duloxetine patients.
  The majority of AEs was mild to moderate and resolved within 30 days of treatment. Still, in many patients the most common AEs (dry mouth, fatigue, insomnia and constipation) remained for more than 30 days. Among patients reporting dizziness, nausea, insomnia and somnolence, between 12 and 22% discontinued treatment. Among the most commonly reported AEs, 10-15% were reported as severe.
  In total, 20.5% of duloxetine patients discontinued treatment for AEs vs. 3.9% in the placebo group in the four pivotal 12-week studies. Including data from the ongoing open continuation studies, 30.6% of the patients had discontinued treatment at the database cut-off date.
  No deaths that were judged as related to treatment were reported and the number of SAEs was low with little or no association to treatment. Two cases with severe liver disturbances were reported. Although, in both cases other predisposing factors were present and the role of duloxetine was judged as uncertain, an association could not be excluded.
  Among laboratory results the only finding that may be of clinical significance was an increase in transaminases above placebo in duloxetine treated patients and also a higher number of patients with abnormal values. No effects on vital signs of clinical importance were observed. Analysis of ECGs from all patients in the pivotal SUI studies did not reveal any arrhythmogenic tendencies with duloxetine.
Unsurprisingly, long term exposure show a higher incidence of discontinuation (30.6% versus 20.5%) and of SAEs (3.2% versus 1.9%) compared to short-term treatment. Apart from that, the safety profile can be considered similar to that already known.

During the Phase 3 clinical development of duloxetine in SUI patient’s withdrawal symptoms were not specifically considered and only one Phase 2 study looked at a tapering phase at the end of the treatment. Based on the pattern of discontinuation symptoms from studies of duloxetine for all indications, the SPC specifies dose tapering at the time of discontinuation to minimize the risk of symptoms.

As with other drugs with similar pharmacological action (antidepressants), isolated cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation. Adequate warning information of the potential association of suicidal ideation and behaviour with the use of duloxetine, has been included in the Product information.

5. Overall conclusions and benefit/risk assessment

Quality

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

Non-clinical pharmacology and toxicology

Overall the pharmacodynamic studies showed that that duloxetine induced inhibition of 5-HT and NE reuptake. This inhibition suppressed urinary bladder muscular activity in a dose-dependent manner, and enhanced external urethral sphincter activity through centrally mediated (CNS) mechanism. Duloxetine was active in urinary models, indicative of enhancement of serotonin and norepinephrine neurotransmission, with improvement of capacity of the urinary bladder and increased urinary sphincter activity.

The general pharmacology studies are appropriate to support the non-clinical-pharmacology profile of duloxetine.

From the pharmacokinetic point of view, mice, rats, and dogs were the most relevant species for non-clinical efficacy and safety studies. The non-clinical pharmacokinetics properties for duloxetine have been appropriately described. A number of studies concerning the absorption, distribution, metabolism, and excretion of duloxetine in mice, rats, and dogs have been performed. Duloxetine is well absorbed in all studied species, and is extensively metabolised, especially at the liver.

Overall, the toxicology programme revealed the liver as the target organ related to duloxetine administration in all species tested.

The dog was chosen as the non-rodent species for use in the toxicology programme.

Efficacy

The efficacy of duloxetine 40 mg given twice daily in the treatment of SUI was established in four double-blind, placebo-controlled studies, that randomised 1913 women (22 to 83 years) with SUI; of these, 958 patients were randomised to duloxetine and 955 to placebo. The primary efficacy measures were Incontinence Episode Frequency (IEF) from diaries and an incontinence specific quality of life questionnaire score (I-QOL).

Overall, although not statistically significant in all trials, duloxetine has shown a consistently greater effect on IEF and QoL than placebo. The magnitude of the relative effect on IEF is about 50% with a placebo response ranging from 27% to 40%. When patients were analysed according their incontinence severity at baseline (< 14 IEF/week and ≥ 14 IEF/week) the improvement was less pronounced for the less severe stratum of patients without a clear translation into a quality of life benefit. Hence the indication has been restricted to moderate to severe stress urinary incontinence.

The lack of documented long-term effects is also reflected in the SPC.
Safety

The primary safety database from short-term trials (12-week, placebo-controlled clinical trials in patients with SUI) included 958 duloxetine-treated patients and 955 placebo-treated patients. This represents 190 patient-years of exposure at 40 mg twice daily. Data on long-term exposure have been less extensively reported as they emanate from ongoing studies.

Duloxetine is a drug with highly variable pharmacokinetics and many factors affect the systemic exposure (gender, age, renal and hepatic function, smoking status, CYP2D6 status, drug-drug interactions)

AEs occurred significantly more often in the duloxetine group than in the placebo group in the pooled 12-week studies. The most common AEs were nausea (23%), dry mouth (13%), fatigue (13%), insomnia (13%), and constipation (11%). Headache, dizziness, somnolence, and diarrhoea occurred in 5-10% of the duloxetine patients. Others AEs, including vomiting, anorectic disturbances, libido disturbances, sleep disorders, lethargy, and weakness occurred in 1-5% of the duloxetine patients.

The majority of AEs was mild to moderate and resolved within 30 days of treatment

In total, 20.5% of duloxetine patients discontinued treatment for AEs vs. 3.9% in the placebo group in the four pivotal 12-week studies.

Benefit/risk assessment

Stress urinary incontinence is a common and chronic condition in women. While not life-threatening, it can have a significant negative impact on the psychological well-being, social functioning and overall quality of life of those it affect. At present there is no approved pharmacological treatment for this condition.

Duloxetine has shown an effect in patients with stress urinary incontinence in terms of both frequency of incontinence episodes and subjective measures as Quality of Life, Patient Global Impression and Clinical Global Impression. Data provided by the Applicant indicate that, although modest, the observed effect is clinically meaningful in patients with moderate to severe stress urinary incontinence, especially when the drug is combined with Pelvic floor muscle training. Although the long-term safety database is limited, the tolerability profile of duloxetine seems acceptable. Therefore, and considering that no pharmacological alternative is available for the treatment of stress urinary incontinence, duloxetine might play a role in alleviating the symptoms of such an uncomfortable clinical condition. A positive benefit-risk can be concluded.

Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the benefit/risk ratio of duloxetine in the treatment of women with moderate to severe Stress Urinary Incontinence was favourable and therefore recommended the granting of the marketing authorisation.